passion transformsif theres one thing employees share p assion years passion people powered every invention every product every breakthrough weve brought human health year extraordinary testament fact passion part people johnson johnson family companies dna compels us work corporation devoted improving health wellbeing people world passion inspired values embodied credo employees johnson johnson family companies practiced treasured handed generations credo underscores personal responsibility put needs wellbeing people serve first liberates passion deepens commitment delivering meaningful health innovations johnson johnson take pride knowing daily work makes difference world years come passion continues transform human health cover olga vasukova like many colleagues johnson johnson llc moscow supporting governments initiative modernize health care personal call action reinforced smile fathers face obvious joy daughter sashas heart time papa pays visit story see chairmans letter shareholders improving health wellbeing people around world vital important business perhaps worlds meaningful business reason attracts exceptional people capable skilled possess genuine passion making difference peoples lives worlds thanks dedication people advancing human comprehensive broadly based health health wellbeing johnson johnson delivered solid financial results taking aggressive steps position care company johnson johnson corporation future growth privileged play role helping millions william c weldon chairman board directors chief executive officer people well stay well considered young hip replacement preserve thanks passion hard work ingenuity bone return active lives new medicine people introduced hundreds significant new products tibotec therapeutics division ortho biotech products lp line extensions across enterprise many advances offers hope many treatmentexperienced hiv patients discovered invented johnson johnson scientists thought running options developed rd organizations among small sampling new products new neutrogena aveeno skin care products introduced featuring patented breakthrough longlasting protection time focus growing broad base suns harmful uva rays new diagnostic test human health care led significant acquisitions across veridex llc allows doctors know enterprise including pfizer consumer healthcare breast cancer surgery whether womans cancer spread solidified position worlds premier consumer health lymph nodes new implant technology care company six key acquisitions medical technology depuy orthopaedics inc enables adults previously strengthened position worlds largest net sales diluted earnings per share dividends paid per share billions dollars dollars dollars chairmans letter broadly based medical also advancing unprec opportunity devices diagnostics edented pace means company hold opportunity scientific scientific innovation position innovationincluding major franchises including innovation innovation technology pharmaceuticals convergencehas never strengthened virology technology promising especially business us launch broadly based companies prezista darunavir convergencehas never capacity adopt patients diagnosed commercialize new promising treatmentresistant hiv technologies quickly continue build pipeline course systemic especially broadly products targeting increases demand create worlds difficulttotreat countervailing social forces based companies diseases also signed several including pressure health important licensing agreements capacity adopt care budgets political pressure position us growth access affordability therapeutic areassuch commercialize new health care services oncology diabetes products demand lowcost hepatitis cwhere serious technologies quickly alternatives increasing unmet needs exist competition challenges science rapidly evolving intellectual property thanks dedication forces impact virtually people advancing human health wellbeing participants health care marketplace johnson johnson delivered solid financial results approach addressing underlying challenges taking aggressive steps position corporation find right path stakeholders sustainable future growth worldwide sales grew record longterm growth johnson johnson years billion growth rate percent operational credo focused people responsibilities wide growth percent range stakeholders customers patients family members net earnings adjusted billion grew employees communities shareholders long percent outpacing sales growth achieved acquainted need find winwin propositions solid earnings growth year slower sales growth stakeholders around world also understand continued focus productivity cost management solid financial returns come well adjusted earnings per share grew percent higher rate earnings due completion billion winning formula growth johnson johnson unique share repurchase program announced march company world change constant johnson johnson enduring company strong growth opportunities never uniqueness goes well beyond exceptional exciting time worlds comprehensive longterm financial results delivered many broadly based health care company products services decades derives management philosophies bring high value increasing demand define unique business model guided us progress science opening new horizons improving extraordinary changes science economics human human health wellbeing health much past century demographic geographic trends drive even founded shared values embodied credo stronger demand categories health care products broadly based human health care years ahead much developed worlds population decentralized way operate business aging expectation maintaining full active managed long term life furthermore rapid growth demand health followed time strategic principles products services developing nations creating global source enduring strength ability adapt expansion opportunity especially companies like flourish dynamic everevolving industry encourage capacity execute many markets successful operation businesses near products sold countries making us ideally long term suited capitalize trend chart next shows exceptionally equally important science health wellbeing consistent sales growth attained longer term evolving rapidly thanks part wealth information logged th consecutive year sales increases flowing sequencing human genome moreover rd consecutive year earnings increases adjusted scientific breakthroughs outside biologyin materials special charges th consecutive year dividend science electronics computer science technologies increases record matched underpin sciencebased health care solutionsare companies history johnson johnson annual reportfinancial highlights johnson johnson subsidiaries sales dollars billions change change sales customers millions net earnings millions percent return average shareholders equity diluted net earnings per share cash dividends paid per share market price yearend close believe strategic principles responsibility stockholders concludes served us well past even relevant future saying operate business according growth prospects look ahead strengths responsibilities embodied credo stockholders required environment characterized historic realize fair return levels rising demand increasing economic credo connective tissue allows us manage political complexity broadly based highly decentralized company long term credo foundation three credo strategic foundation foundation strategic principles give us many distinct advantages principles deeply held common set values embodied yearold document called credo see back cover strength breadth since began robert wood johnson ii wrote credo diversify beyond hospital products johnson johnson johnson johnson became publicly traded company fully committed broadly based human since time guided actions johnson johnson health care today leadership presence three people levels parts world distinct segments health care industry consumer health put simply credo challenges employees put care medical devices diagnostics pharmaceuticals needs wellbeing people serve first asks broadly based three diverse segments health care supervisors colleagues treat fellow employees helped us sustain consistently superior performance respect dignity spotlights responsibilities johnson johnson shareholders years communities live work well one portion business experienced strong growth world community part says final another may require steppedup investment future chairmans letter sales segment research expense shareholder return billions dollars medical devices millions dollars total diagnostics sp index sp pharmaceutical index sp health care equip index johnson johnson pharmaceutical consumer year compound annual growth rate growth downturn economic conditions one health tralized businesses grow businesses faster care segment may offset growth another segment competitors driven innovate bring greater even important breadth offers four key value marketplace internal discoveries applica advantages enable us elevate performance tion new science technology inlicensing acquisition first closeness customersour strong believe decentralized approach running partnerships scientists professionals across many business yields better decisionsin long runfor patients fields within human health across many geographies health professionals customers identify rapidly capitalize attractive decisionmakers close customers business opportunities emerging human health better position understand needs spot emerging opportunity breadth enables us finally decentralized approach managing quickly deploy necessary resources develop business tremendous magnet talent gives second breadth allows strategic transfer knowledge people room grow room explore new ideas thus new technology talent capabilities internally across developing skills careers business platforms across business segments several examples strategic transfer knowledge across business strength focus long term manage business platforms business segments highlighted marathon rather sprint source following pages stories people behind enduring financial strength innovative products introduced managing business long term keeps us focused third breadth also gives us clear advantage underlying performance business conscious converging technologies increasingly breakthrough innova ongoing performance time frames focus keeping tions new adjacent markets enabled careful businesses healthy long term integration multiple technologies people accus forces us anticipate capitalize change tomed working within across business segments look future businesses many different incorporate technological breakthroughs achieve impor lensesthrough eyes new customers new markets tant innovations customers like access new technologies new fiscal realities desire capitalize knowhow proprietary information technology resources changes global health care environment favor many companies within corporation consumerdriven health care part rationale finally breadth also allows us leverage scale acquiring pfizer consumer healthcare increasingly competitive global environment managing business long term leads us efficient application deployment resources around intensify investments needed maintain leadership globe weve able optimize cost infrastructure positions key growth markets particularly areas manufacturing finance longterm view enables us take prudent risks procurement information technology innovative ideas completely new ways things new better products alternative therapeutic strength decentralized approach decentralized approaches novel technologies new better manufacturing manner operate businesses marries best processes longterm investmentssuch qualities smaller companiesan entrepreneurial drive investment veridexs fledgling cellular molecularlevel growth close proximity customerswith resources diagnostics platformhave power potentially transform knowhow investment capital fortune company practice medicine see initial strategic approach gives us many advantages investment ethicon endosurgery inc years ago centralized operation one strong sense ownership led revolution minimally invasive surgery entrepreneurship agility accountability seldom seen managing long term enables us make smarter large multinational corporations leadership acquisitions deliver longterm shareholder value employees operating companies around world willing take important challenging work often requiring intensely competitive look leaders decen sustained efforts order achieve significantand possibly johnson johnson annual reporttransformationaloutcomes long view also gives us courage walk away four strategic principles negotiating table believe price tag acquisition deliver strong longterm return shareholders investment managing long term also entails careful evaluation longterm broadly based prospects businesses regularly evaluate business human health product portfolios make tough decisions curtail projects sometimes divest managed entire businesses decentralized finally managing long term approach along shared value systemhas long term helped earn us reputation company worthy trust trusted opens doors opportunities growth opens doors prospective business partners new product ideas new technologies founded shared values doors research institutions working health advances tomorrow opens doors policy makers advocacy groups want hear perspective improving health care founded shared values foundation strategic principles system countries see stories deeply held common set values embodied yearold document pages called credo see managing business long term allows us focus shaping future broadly based human health broadly based three diverse rather simply reacting change segments health care helped us sustain consistent superior performance johnson johnson shareholders years even important breadth offers four key advantages enable consumer health care highlights us elevate performance see momentous year consumer health care businesses completion decentralized approach decentralized manner operate acquisition pfi zer consumer healthcare businesses marries best qualities smaller companies pch december solidifi ed position resources knowhow investment capital fortune company worlds premier consumer health care see company extending leadership managed long term managing business long term consumer health categories keeps us focused underlying performance business worlds diverse consumer health conscious ongoing performance time frames focus keeping portfolio large sustainable platforms businesses healthy long term see growth approximately half pch sales outside us acquisition also expands reach health wellbeing throughout world attractive highgrowth markets brings us growing turning otc medicines nonprescription enduring brand names complement portfolio solutions meet health needs higher levels dispos strong iconic brands broadens oral health care able income developing nations creating increased business signifi cant franchise billion demand consumer health products regions sales transforms overthecounter otc large populations business nearly doubling size solidifying position pch acquisition another good worldwide leader nonprescription medicines year consumer health care businesses reached acquisition substantially diversifi es otc portfolio nearly billion sales total consumer health provides entry highpotential categories businesses introduced new products smoking cessation signifi cant line extensions helping drive total sales growth strategically acquisition vitally important percent see year review consumer health care market consumer health care products becomes pages increasingly attractive several demographic social believe pch acquisition along access shifts favor increased demand consumer health products scientifi c knowledge technologies fl owing consumers taking greater interest responsibility pharmaceuticals medical devices diagnostics chairmans letter businesses position us continue worlds leader tablets jurnista prolongedrelease tablets hydromor scientifically based professionally endorsed consumer phone hcl prezista darunavir ionsys fentanyl health care products iontophoretic transdermal system also received approval several significant line extensions key products major pharmaceuticals highlights overall environment markets including risperdal risperidone us pharmaceutical industry continues challenging treatment irritability associated autism remicade throughout world downward pressures pricing infliximab us treatment chronic severe reimbursement continue patents multibilliondollar plaque psoriasis pediatric crohns disease addition productsincluding ownface expiration received authorization european health coming years nevertheless good year authorities restore subcutaneous administration pharmaceuticals businesses actions took early eprex epoetin alfaerypo epoetin alfa anemia patients chronic kidney diseases mid communicated investment community plans file secure approval new prescription medicines end im pleased report remain track meet goal fortified pharmaceutical pipelinealready robust point historyby adding four new compounds strategic licensing agreements include two potential insulin sensitizers treatment diabetes oncology compound novel protease inhibitor treatment hepatitis c reorganized pharmaceuticals business create three franchises one focused diseases central nervous system cns internal medicine im second focused biotech immunology oncology bio third focused virology cnsim business responsible sustaining leadership positions cns pain management building new global growth platforms antibacterials cardiovascular disease bio business responsible strengthening global leadership immunemediated inflammatory disorders anemia management expanding emerging global growth platform oncology indicated previ ously virology business working toward building leadership positions range virologic diseases high unmet medical needs medical devices diagnostics highlights medical devices diagnostics mdd segment performed well solid organic growth coupled strategic acquisitions across segment position us future growth mdd shared values help us earn trust respect see year review medical devices diagnostics essential company devoted improving pages health wellbeing people world total sales grew percent bringing mdd businesses christine poon billion annual revenue continue vice chairman board directors largest globally diverse medical devices diagnostics business world decade strengthen pipeline starting pay innovation continues drive strong organic growth new drug approvals strong nearterm pipeline mdd businesses percent mdd positioned us mitigate impact patent sales came products introduced past five years expirations remainder decade since beginning acquired six total sales growth pharmaceuticals segment strategically important medical device companies several percent continued build future growth examples focus complementary growth hand many significant accomplishments business innovations llc leader plating technology wrist segment see year review pharmaceuticals hand fractures important addition fastgrowing pages trauma business within depuy orthopaedics inc franchise received regulatory approvals market four acquisition animas corporation leader insulin new productsinvega paliperidone extended release delivery systems enable lifescan inc world leader johnson johnson annual reportdiabetes monitoring devices commitment management enter diabetes treatment read stories behind market even important stories key philosophy anchored acquisition initial business developments step lifescans plan following pages trust value system embodied develop integrated solutions youll see believe human total management health exceptional credo allows us patients disease business type future medical systems people attracted deal complexities sa company develops businessand specifically manufactures markets johnson johnsonare balancing shortterm arthroscopic systems adds driven ordinary strength depuys fast desire serve succeed longterm growth growing sports medicine business business emphasis remain highly minimally invasive procedures optimistic future acquisition vascular growth prospects control systems inc business improving human ethicon inc adds momentum ethicons womens health health wellbeing based unprecedented demographic portfolio addition less invasive treatment options geographic social trends uterine fibroids related symptoms broadly based comprehensive company two acquisitions add critical mass cardiovascular fieldone wellbalanced portfolio businesses businesses ensure medical adds complementary post consumer health care medical devices diagnostics catheterization closure technology femoral artery pharmaceuticalswe harness benefits increasing important brings critical mass cordis demand continuing work closely various corporations rd talent pool premier advanced stakeholders throughout health care system research development facility interventional management philosophy anchored value system cardiology near san francisco conor medsystems embodied credo allows us deal complexities unique controlled drugdelivery technology balancing shortterm longterm growth explored across range therapeutic categories based outlook growth health care immediately contributes development next confidence strategic approachincluding unique generation technologies aimed advancing standard benefits broadly based health care businesseswe care treatment cardiac vascular diseases committed delivering capitalefficient profitable growth believe impressive number new product intro participating fastestgrowing segments human ductions many exciting products mdd pipeline health care acquisitions made many bring us building sustaining leadership positions based unique competitive advantageswill enable us remain superior science innovation worlds leader medical technology accelerate growth managing businesses achieve superior rates exciting health care segment return shareholders thanks concluding id like take moment real strength corporation always acknowledge two retiring board members exceptional people talent drive passion contributions company aspirations make difference world traits first wish recognize ann jordan retire enable us bring forward innovations improve lives board directors april mrs jordan wellbeing people world traits elected board years ago brought deep embodied character quality peoplehave also experience health care social services bear helping helped us deliver superior performance shareholders guide company especially roles chairman continue source enduring success nomination corporate governance committee member future compensation benefits committee past chairman public policy advisory committee also wish thank recently retired vice chairman board directors chief financial officer william c weldon robert j darretta years commitment chairman board directors johnson johnson steady hand financial helm chief executive officer corporation past decade bob march instrumental helping us deliver consistent sustainable superior performance visible vocal excludes inprocess research development guidant acquisition agree proponent enduring strategic principles ment termination fee see reconciliation nongaap financial measures chairmans letter stories behind every new product family companies introducesbehind every one partnerships advance health wellbeing people around world stands team people passion story stories behind accomplishments reveal much character people aims company read stories hope youll see strategic principles play realityhow liberate people pursue consumer research insight solve scientifi c puzzle pursue big bold vision collaborate colleagues half world away make real diff erence peoples lives passion transforms fun sun years bicoastal cooperation two skin care scientists working two diff erent johnson johnson companies resulted remarkable sunprotection breakthrough patented advanced sunscreen system stronger eff ective longerlasting protection dangerous kind damage suns rays infl ict human skin dermatologists calling one biggest link sun exposure conse sunprotection innovations last years quent need protection manufacturers paradigmtransforming technology skin care products began adding new sun provides stable broad protection protection remarkably wide range dangerous uva rays penetrate deeply skin care products long spf skin layers reducing collagen elastin sun protection factorbecame price uva rays clinically implicated sun market entry added benefi induced aging skin well skin cancer every new skin care product incidental exposure sun cumulative consumers getting false sense explains curtis cole phd photobiologist security high spf numbers bicoastal teamwork senior director skin care technology sunscreen products even containing curtis cole phd left johnson johnson consumer products uva fi lter avobenzone avoben rick woodin company division johnson johnson collaborated years zonethe eff ective broadspectrum fi lter consumer companies inc skillman nj blocking uva raysbreaks apart molec time single tiny photon sunlight unprotected ular level absorbs energy sunlight early skin could become tipping point cancer lab team tried photostabilize avobenzone adding evidence uva damagewhich include wrinkling another chemical many years eff ort found sagging mottlingmay reveal years chemical called dehn would help stabilize avobenzone unprotected skin exposed sun contrast percentand wanted higher level stability uvb rayswhich attack skins uppermost layers cause sunburn matter minutes solution arrives added third ingredient oxybenzonewe saw interesting chemical mechanism ten years research took years research action dehn accepts excess energy absorbed development work dr cole west coast partner avobenzone transfers oxybenzone converts rick woodin photochemist director product uv light harmless red light without sacrifi cing development neutrogena corporationto crack uva avobenzones ability absorb incoming photons protection code help franchiselevel marketers seeking years adds cole develop portfolio skin care products unparalleled sun finally remarkably longlasting sunscreen protection neutrogena aveeno trademarks would break sunlight would block recalls dr cole mids american academy harmful rays fi nal touch added conven dermatology launched intensive publiceducation program tional uvb fi lters fortify spf provide people true skin cancer raised consciousness around world broadspectrum protection johnson johnson annual reportsoaring success neutrogena aveeno advanced sunscreen products flying retail shelves light textured easily absorbed provide maximum protection suns damaging rays dr curtis cole phd photobiologist senior director skin care technology johnson johnson consumer products company advises important people remember reapply sun protection swim parents remember reapply childrens skin take break water explains woodin curt able write natural ingredients clinically proven even johnson johnson patent new synergistic technology skin tone improve blotchiness discoloration affording intellectual property protection within current caused previous sun exposure aveeno regulatory guidelines enabled rapid product deployment products contain patented total soy complex us marketplace idea good execu natural moisturizer vitamin e strong antioxidant tionso worked hard give consumers delightful slows uvainduced free radical chain reac aesthetic experience possible new technology tion thought cause wrinkling otherwiseyouthful skin aveeno calls new patented technology active gotomarket strategies neutrogena photobarrier complex aveeno successfully launched new lines skin care products containing newly patented advanced sunscreen whats next curt working together technology neutrogena rolled five new decade exciting new exponentially transforma consumer products special one dermatologists tive projects says woodin thats people become dispense calls new technology helioplex scientiststo break barriers bring forward new inventions aveeno launched five new advanced sunscreen products advance boundaries technology american optometric association recognizes vistakons uvblocking lenses cristina schnider director associations aoa commission dr derrick artis director customer medical affairs vistakon division ophthalmic standards development also played role johnson johnson vision care inc contact lens lines offer uv securing aoa seal adds pleased oversee efforts se protection hope generate awareness cure acuvue advance provide similar absorption levels explains potential lenses help acuvue oasys brand contact dr schnider acuvue advance reduce cumulative lenses firstever seal acceptance acuvue oasys brand contact lenses effects uv radiation dr derrick artis ultraviolet absorbing contact contact lenses meet shown increase chance dr cristina schnider lenses american optometric highest uvblocking standards developing eye problems later life fun sun passion transforms social responsibility f olga vasukova personal responsibilities feels employee johnson johnson llc moscow support governments initiative modernize health care given happened father could personal olga studying eyes harvard business school employees johnson johnson papa nikolay vasukov came family companies serving russia russia visit one night cis russian governments dinner nikolay felt chest pain new initiative nothing less phoned ambulance challenge improve health recalls vasukova friends loved ones strategic affairs director surprisingly people undertake johnson johnson llc medical mission resultsdriven mix russia headquartered moscow professional commitment youthful took papa hospital vigor intense personal interest doctors said narrowing blood says naira adamian country manager vessels restricting blood flow janssencilag russia coronary arteries performed coronary artery catheter firstever award ization inserted baremetal stent civic initiatives one artery keep open stent throughout russia cis made cordis corporation local johnson johnson companies today nikolay vigorous support training programs medical yearold visits vasukova professionals underwrite yearold granddaughter sasha educational philanthropic often daughter energy efforts advance new health several years ago interventional cardiologists burn papa keeps right inserted cordis baremetal stent one care agenda says vasukova nikolay vasukovs coronary arteries today russian enjoys visits daughter olga government recognized energetic granddaughter sasha wouldnt wonderful contributions presenting kremlin recently issued directive calling johnson johnson inaugural annual corporate comprehensive upgrades russian health care system social responsibility award selection committee became personal call action wouldnt wonderful award leading representatives three sectors every russian grandfather could get kind medical care russian societypoliticians scientists artists papa received asks vasukova award cited many johnson johnson civic initiatives russian government couldnt agree speeches including supporting kremlins directive russian president vladimir contribution victims putin declared wants see decisive yet prudent steps terrorist attack school beslan chechnya taken every city town village modernize health support children cerebral palsy congenital heart care throughout russia entire commonwealth disease leukemia blindness independent states cis support major hivaids philanthropic programs good corporate citizenship throughout russia johnson johnson family companies supports educational philanthropic efforts advance nations new health care agenda russian government recognized contributions presenting company inaugural annual corporate social responsibility award top johnson johnson annual reporttogetherness joining hands run across moscows red square johnson johnson llc employees left right igor nemchenko managing director consumer group russia vladimir makatsaria managing director johnson johnson medical russiacis naira adamian country manager janssencilag russia sandy mcintire managing director consumer group ukraine cilag gmbh international serious responsibilities taking seriously respon furthermore consumer company brands sibilities outlined credo johnson johnson llc recognized prestigious effie gold became largest health care company effie trusted brand awards awareness russia says vladimir makatsaria managing director trust theyve earned among russian consumers says johnson johnson medical russiacis words igor nemchenko managing director consumer group russia see business milestone positive side effect strive bring science consumer health prod wholehearted effort support government seeks ucts thats important contribution health provide affordable goodquality health care every russian wellbeing people serve russia adult child everywhere june johnson johnson llc opened new squaremeter office heart moscow bring local active partner active partner employees one roof first time first sight russian government supporting health care reform greets day credo etched large glass panel education says adamian health science policy national award corporate social respon makers sought counsel range best practices sibility previous year johnson johnson llc received weve able draw upon knowledge colleagues moscow employer year award human throughout johnson johnson family companies resources management respected russian business journal employees playing positive role future explains makatsaria tantamount second national russian health care theyre playing role award percent companies presence remarkable passion conviction russia headquartered moscow personal dimensions social responsibility passion transforms vision beautifully nce success new product exceeds even creators expectations case point new line acuvue brand contact lenses designed specifically enhance attractiveness dark asian eyes fact new line disposable contact lenses adds literal layer meaning saying beauty eye beholder lens features dark outer ring embedded within lens makes wearers iris appear larger extremely subtle effect many female even developed response asian customer research insights male asian contact lens wearers notably korea japan helped day acuvue become market leader find particularly desirable many involved developing new brand latest addition line day acuvue define pleased product exceeded expectations one vivid style cosmetic contact lenses launched korea koreanborn employee johnson johnson vision care inc singapore china japan fall style karren koo confident outset offers dramatic option want vibrant irisenhancing concept would strike responsive chord irisenhancing effect contact lens wearers asia lens lens new day acuvue define tale two karens kooat time latest strong pipeline vision care products launched johnson johnson vision care inc marketing manager based past two years seoul koreadetected consistent response market example acuvue advance brand focus groups asian women kept saying wanted lens contact lenses astigmatism made debut first would make eyes appear bigger distinctive koo silicone hydrogel daily wear contact lens people astig recalls kept coming research time matisma vision condition common millions children additional research showed customers wanted teenagers adults addition day acuvue moist brand effect beautiful yet subtle natural contact lenseswith breakthrough lacreon technology born words lenses needed launched year europe middle east africa beauty secret koo adds felt certain would considerable success japan day acuvue moist respond favorably could combine subtle beautydriven become fastestgrowing product category iris enhancement along outstanding health benefits new irisenhancing product day acuvue define popular day acuvue lenses brand contact lensesincluding firstlaunched accent meeting meeting koo pressed newproduct style new vivid stylehas already proved wildly idea colleagues marketing rd gentle popular asiapacific region new brand persistence finally rewarded invited dr karin mccarthy left karren koo partner another karen half world away native johnson johnson annual reportat right dark outer ring embedded within lens day acuvue define makes iris appear larger denmark dr karin mccarthy manager cosmetics stay close voice customer get product development cosmetictints platform research right clinical trial made subtle refinements development center vistakon division would dramatically enhance appeal johnson johnson vision care inc jacksonville fla day acuvue define launched korea koos wontbedenied competitive spirit found kin november japan biggest asian market dr mccarthy former olympian represented denmark february next year new lenses swimming events says dr mccarthy mutual friends rolled china singapore taiwan hong kong thailand company agreed karren along market malaysia response extremely positive among research partners perfect professional tag team able female consumers ages innovation also hand marketbased sciencebased attracted new people contact lens category says koo issues might arise developed exciting new beautyenhancing product line socalled asian eye strong vision vision business year also marked th anniversary johnson johnson vision turning point japan critical turn development care business whichmuch like beauty contact lenses product clinical trial japan asian womenwas created paradigmshifting approach essentially virgin market irisenhancing lenses based directly consumer insight acuvue worlds course study dr mccarthy ensured cosmetic effect first disposable contact lens prototypical day acuvue define lens would overall perspective vision care business aims appealing japanese consumers equally important provide healthy vision everyone everywhere every gathering input eye care professionals ensure lens day global market leader disposable contact design met needs lens market turn koo learned japanese consumers preferred blazing new trail global marketplace subtlest possible appearance iris enlargementthe equiva contact lenses putting greater emphasis satisfying lent extrathin eyeliner eye makeup product special needs desires customers different geogra feedback japanese consumers gave karin phies cultures says koo day acuvue define nuances mull recalls koo always knew perfect example vision beautifully passion transforms power knowing breast cancer surgeon never faces frustrating midoperative moment close womans surgical wounds without knowing whether breast cancer cells metastasized spread patients lymph nodes answer comes rightbut phd scientist led early days later biopsy report development genesearch becomes available news platform vice president bad doctor call patient europe middle east africa emea whose wounds healing ask orthoclinical diagnostics inc come back moremore orthoclinical new diagnostic preop counseling signoffs platform genetic detective anesthesia surgery hunter rogue dna looks recovery pain scarring molecular level dna anxiety present dna indicates fortunately alltoofamiliar spread cancer scenario need never occur detecting rogue dna lymph nodes essential staging treating waiting new disease precision adds atkins dnabased diagnostic tool finding however thought genesearch breast lymph node nearly impossible due limitations bln assay deliver test results underlying technology minutes breast team working project thought cancer patient still operating outside box developed novel table false starts healing approach detecting rogue dna waiting several days news genesearch brand veridex intraoperatively good bad secondsurgery develops products based molecular heartaches technology gene expression profiling vanguard new era gene arrays one help physicians genesearch assays use today two every three medical detect presence cancer earlier molecularlevel patented technology decisions based upon vitro diag diagnose stage andor accurately characterize disease nostic testing conducted test tube controlled far quickly ever environmenta field orthoclinical worldwide genesearch quickly obtain result leader says roy davis orthoclinical company group status sentinal lymph node says dr jeanmarie chairman focus shifts lab operations patient nogaret chief breast surgeon institut julesbordet brussels outcomes diagnostic tools like genesearchand another belgium benefit patient medical veridex platform cellsearchwill help write next big team economical chapter history medicine represent vanguard new era cellular molecularbased diagnostics pioneering diagnostics new genesearch diagnostic enable doctors manage patients back wellness test pioneered veridex llc genesearch bln rather coping illness test entered european market mid compliance orthoclinical forefront major transformation eu vitro medical device regulations received happening diagnostics companys approach two favorable fda advisory panel review december pronged veridex introduces new diagnostic platforms earlier doctor detect metastasized breast cancer oncology orthoclinicals franchise development group womans lymphatic tissue better outcomeand actively engaged identifying new biological markers thats genesearch comes explains david atkins select categories major unmet medical needs many johnson johnson annual reportnovel diagnostics working identify novel diagnostic prognostic markers says yixin wang left phd executive director research development veridex genetic detective looks dna present dna indicates spread cancer explains david atkins right phd vice president emea orthoclinical diagnostics inc led early development genesearch markers validated become foundation new veridex molecular testing pipeline highvalue diagnostic teststests potential wangs orthoclinical responsibility support identify disease states earlier stages ever pharmaceutical research development teams biomarker cellsearchunveiled identifies enumerates evaluation drug development characterizes circulating tumor cells directly name game detecting cancer cells wholeblood sample currently available us use earliest possible point says wang thats metastatic breast cancer clinical trials progress genesearch cellsearch platforms application additional cancers designed look forward bringing series genesearch cellsearch tests market still come working project leader collective longterm dream orthoclinical atkins genesearch yixin wang phd executive veridex says davis world cancer rarely director research development veridex says wang fatal diabetes never becomes fullblown researchers la jolla working expand heart attacks circumvented early detection genesearch cellsearch facilitate early detection european introduction genesearch bln cancers also working identify novel diagnostic test testament way making prognostic markers major types cancer support dream reality power knowing passion transforms humans vs microbes hroughout history humanitys worst enemies infectious diseases caused microbesonecelled small multicelled life forms infectious diseases caused bacteria viruses one important causes mortality centuries continue medical challenge says paul stoffels md company group chairman research development cns central nervous system internal medicine founder tibotecvirco company acquired specializes new treatments viral infections widely spread epidemics called pandemics one deadliest hiv since infected estimated million people killing million imaging aids globally technology tuberculosis million portrays humanitys leading cause people worst enemies death infected case hiv infectious disease hepatitis c astounding worldwide virus hcv detail year milestone sciences battle global infectious diseases among greatest unmet hiv years since first case aids medical challenges generation says julie mchugh unnamed reported centers disease control company group chairman virology infectious diseases like says stoffels dedicated much career battling hiv hcv tb truly global health issues require worlds lethal viruses years since pharmaceutical industry create innovative solutions first clinical trial antiretroviral drugs inhibit developing new bestinclass compounds hiv genetic material patients blood also bringing medications patients need years since debut first protease inhibitors industrialized developing countries prevent virus creating many billion innovative science addresses urgent needs believe new copies daily hivpositive patient opportunity build new sustainable business real impact epidemics worldwide new protease inhibitor moreover year johnson johnson operating company launchedin record unique rd process prezista result unique timea new protease inhibitor pi patients pharmaceutical research development process relied failed previous therapies another pi new drug hiv drugresistance insights gleaned diagnostic tools prezista darunavir also known tmc marketed pioneered virco affiliate tibotec virco performed us tibotec therapeutics division ortho biotech diagnostic tests chart molecular level products lp countries tibotec divisions types resistant hiv viruses worldwide tibotec used within janssencilag companies signals start information design molecule would able new global virology business franchise johnson johnson inhibit replication prevalent drugresistant franchises pipeline robust novel investi strains virus gational medications hiv hepatitis c hcv beyond resistance truly benefit patients also tuberculosis tb tb one important opportu concerned efficacy safety tolerability conve nistic infections hiv patients throughout world nience prezista important new option treatment johnson johnson annual reportwhere began paul stoffels md right company group chairman research development reunited mechelen belgium three founding members aidsfighting research team clockwise bottom hilde azijn senior scientist tibotec clinical virology kurt hertogs vice president tibotecvirco scientific operations mariepierre de bethune vice president tibotec clinical virology experienced adult patients failed stoffels recalls late socalled cocktail resistant one protease inhibitor may allow drug therapies seemed turned aids manageable patients lived low level virus years chronic disease much like diabetes hidden reality attain undetectable viral load goal consistent virus continuing build resistance threatening current treatment guidelines says roger pomerantz md destroy hopes people working hard facp president tibotec research development live full productive lives patient hearing respect development prezista taught hiv infection become drugresistantand viral us great deal treat global infectious disease load increasing decreasingis secondworst day general continues pomerantz showed us longterm life exceeded day physician gave suppression viruses microbes requires development original diagnosis compounds fit virus neatlyand likewise fit felt go extra mile patient patients needs additional studies ongoing evaluate matter long arduous task aheadso put longterm outcomes prezista therapy heads hearts hands work exceptional commitment entire organization tibotec virco science hero yearlong behindthescenes within record time able discover develop novel story tibotec created prezista illustrates nimble drug building new organization people creative science able find way increase core success entire team committed making genetic barrier resistance insidious smart virus difference patients living hivaids globally proved master disguise mutation tibotecvirco vice president scientific operations opportunistic survival kurt hertogs stoffels side beginning humans vs microbes discipline paid five years elapsed first study humans january submission filings december says stoffels drugdevelopment terms extremely short time deep commitment hiv addition prezista known tmc throughout development process tibotec two novel antiretroviralstmc tmcin development investigational drugs nnrtis nonnucleoside reverse transcriptase inhibitors tmc latestage develop ment first investigational nnrti show significant activity patients prior nnrti failure clinical trials also conducted investigate use combination prezista tmc early development compound highly potent successful could become backbone fixeddose combination therapy single pill company continues create path world hiv another nnrti compound tmc licensed company international partnership microbicides nonprofit product development partnership develop ment vaginal microbicide agreement signed first global health infectious diseases represent greatest unmet royaltyfree licensing arrangement medical challenges says julie mchugh company group chairman kind microbicide research virology adds roger pomerantz md facp president tibotec research approach since development new compound prezista fits hiv neatly repeated manufacturers making extremely difficult virus mutate says team engineered failure creating hiv women special study research front timeline gave specific details research tibotec therapeuticsthe companys us marketing development function daytodayand eventually sales clinical arminitiated largest clinical hourtohourbasis covered walls tibotec study ever conducted among treatmentexperienced adult facility mechelen belgium posters six feet long women hiv grace gender race clinical three feet wide posters illustrated interplay experience study comparing gender differences functions deliverables constant reminder efficacy safety tolerability prezista administered deadlines commitments antiretroviral agents week treatment another original team member mariepierre de bethune period study conducted sites vice president clinical virology says motto throughout us mexico canada also explores racial patients waiting drove us work way paul differences treatment outcomes called faster possible without compromising quality says mchugh although women represent nearly science ethics made many personal sacrifices meet percent infections worldwide vastly highly accelerated timeline instance highoutput represented hiv clinical trialseven though research months restricted vacation times came time date suggests women may tolerate hiv medica work application health authorities core team tions different ways men also suggests certain went offsite remote location northeast belgium complications disease may genderspecific entire week working pm day weve worked closely us hiv community johnson johnson annual reportdeveloping trial grace study collabora providing access medicines says mchugh tibotec tion international partnership microbicides virco believe people need products tmc refl ect deep commitment address hiv ready access finding creative ways ensure treatment prevention options women girls access core part business better access developing nations upon receiving epidemics sights research earliest approval prezista company launched development teams tibotec virco even tibotec global access program initiative hiv within sights unique situation created infectious tmc fi rst novel antitb compound years disease global pandemic tibotec make discovered johnson johnson pharmaceutical antiretrovirals available reduced prices sustainable research development llc laboratories beerse belgium basis people need countries developed tibotec tibotec also recently program includes early fi ling registration prezista obtained codevelopment marketing rights selected countries selected basis several territories vertex pharmaceuticals vx factors including incidence prevalence hivaids promising oral inhibitor hepatitis c virus hcv protease maturity hiv treatment programs pres drug called telaprevir early development ence international hiv programs dossiers already addition tibotec internal preclinical hcv drug submitted countries including discovery programs advancing hcv protease inhib high hiv burden brazil china india south itor clinical studies collaboration medivir ab africa thailand ukraine many least developed years come says werner verbiest general manager countries worldespecially subsaharan african virco bvba virology franchise continue explore nationsthe company actively pursuing agreements use biomarkers diagnostic drug discovery licensing generic manufacturers purposes seeking increasingly personalized eff ective recognize unparalleled challenges posed treatments matter well keep one thing aids epidemic responsibility collaborate forefront work international response pandemic particularly somewhere patients waiting employee volunteers village unfortunately much water upgrade ugandan contaminated microorganisms even cholera tibotec virco employee initiative villages water support larger volunteer project provides support services mulanda including homebased care counseling hivaids patients tibotec virco offi ces mechelen belgium yardley pa cleanwater project taken life employees initiated fundraising efforts research leads back africa early included car washes photographic contest says jens van roey md director global clinical calendar production sponsored triathlons development tibotec time paul stoffels athletic events sales items water working side side clinical caregivers buckets tshirts items contributed individual medical researchers zaire congo one employees including homegrown fruits vegetables poorest countries subsaharan africa began apple juice homemade belgian waffl es notice signs nothing less plaguetocome overemphasize volunteerism isnt vast yettobenamed microbial scourge onesided charity valuable exchange central africa undoubtedly evolving epicenter van roey says twoway streeta constant ensuing years countries uganda dialogue people much teach us suffered terrible losses hivaids says live dignity solidarity broader van roey million adult ugandans jens van roey md tibotec virco sense family amid unrelenting ravages disease colleagues mechelen belgium helping lost epidemic theyve left behind nearly employees also encouraged visit mulanda provide ugandan village fresh water million orphans disease invades every aspect fi rst employee visited village last fall supply children need walk hours lifework home community day collect water employee volunteers see van roey serves liaison new employee eyes like live hiv africa initiated project begun provide support village mulanda near professional dedication instinctively redoubles especially become aware ugandas eastern border kenya project focused efforts providing critical opinion become involved possible earliest sustainable supply fresh clear water village aim reduce morbidity stages hivaids process helps understand hiv pandemic mortality arising poorquality water many mulandan children walk hours every socioeconomic medical problem needed day carry water distant sources sick parents adults back drugs alone humans vs microbes passion transforms restoring joys life w hen patient christopher acted like life party job says markus michel md head physician orthopaedic center munsingen swiss facility worldrenowned preventing correcting disorders bodys support structures including skeleton joints muscles ligaments cartilage years christopher one unmet patient needs alfonsi switzerlands successful spent initial years depuy indemand djsa highenergy bioengineergoes explain professional expected christopher prime exam party late nights end recalls ple todays patient dr michel life came younger informationempowered grinding halt severe hip prob patient engaging surgeons lems caused feel unrelenting discussion treatment options disabling pain year ago adds alfonsi evolving christopher presented demographic profile presents new first words job challenge orthopaedic surgeons meant everythingnow whole tell us patients like christopher life told work looking stateoftheart sur longer fun couldnt play gical interventions offering optimal sports anymore even function faster recovery given driving said allowing patients preserve professional personal relation active lifestyles ships jeopardy worst christopher couldnt remember without geographic boundaries painfree past ever depuy utilize multinational felt likeand couldnt begin multidisciplinary teams imagine painfree future develop best solutions turned christopher changing needs todays needed operation usually hip patients explains professor associated someone twice graham isaac senior engineering markus michel md head physician switzerlands agehe needed hip replacement fellow hips believe worldrenowned orthopaedic center munsingen international approach seniors hip replacement surgery isnt research development differentiates depuy seniors anymore explains stefano alfonsi worldwide orthopaedic industry involve surgeons bioengineers vice president hip marketing depuy orthopaedics inc manufacturers marketers expertise true collaborative leader developing stateofthe art technologies joint effortwith people passion go extra mile reconstruction fact orthopaedic patient population continues isaac teams global surgeons provide getting younger patients unwilling accept longterm insight unmet patient needs surgical procedure pain want maintain quality life additionally bioengineers draw expertise find technical treatment options younger patients expanding solutions clinical challenges product management johnson johnson annual reportback saddle age christophera swiss djdeveloped severe hip problems brought life painwracked halt receiving depuy proxima hip implant bike best team responsibly introduces technologies market require surgeon cut muscles tendons place focus professional education minimizing softtissue damage alfonsi elaborates collaborative product develop depuy asr xl metalonmetal bearings useful ment approach automotive engineers younger people good cortical bone tissue designed system improvement could climb car highperformance bearings larger go test drive team licensed take diameter facilitates lower wear high joint stability patient test drive surgeon thatso compared traditional bearings higher stability rely heavily professional feedback new gives patients greater level confidence inventions efficacy thats exactly depuy regularly con return daily activities new technology venes panels top surgical opinion leaders around world introduced europe us past two years depuy introduced major innovations preserve bone hip replacement surgery dj gets groove back christopher needed highly depuy proxima hip implant device short stable durable joint dr michel chose depuy anatomical stem porocoat porous coating proxima hip combination depuy asr xl specifically designed preserve femoral bone soft metalonmetal bearing tissue advance hip replacement introduced three weeks operation christopher dj europe investigational device exemption already back running show reports dr michel study begins us early booking parties making music driving car depuy proxima hip finds perfect synergy keeping fit even playing sports another depuy innovation depuy microhip says alfonsi year year highest aspiration surgical procedure developed surgeons switzerland help surgeons like dr michel take away patients pain minimally invasive surgical technique restore joy life restoring joys life passion transforms first moments life quiet moment silence babys first breath grand boardroom chinese ministry health echoed joy marinis thoughts waited landmark meeting ministry officials two organizations hoping accomplish asphyxia inability breathe birth million difficult climbing great wall thought marini ms pac babies born every year challenge seemed almost director johnson johnson pediatric institute llc jjpi impossible year china nearly newborns may looked giant mural manmade wonder lose fight lifes first breath others deprived oxygen mid chinas ministry health seeking longer seconds may suffer disabilities partner address overwhelming challenge affected permanent brain damage lives hearts millions families china worldwide neonatal asphyxia strikes one every ministry wanted jjpis collaboration helping babies bornbut happens make difference solve leading cause infant mortality china neonatal babies treated quickly good outcomes international partners chinese ministry health beijing may li far left joy marini second left johnson johnson pediatric institute llc meet chinese ministry health representatives ms cao bin second right director child division madame zhang deying deputy director maternal child division discuss chinas neonatal resuscitation program johnson johnson annual reportfew chinese nurses doctors midwives outside urban hospitals received practical handson training intervene neonatal asphyxiauntil ministry determined save future generations children early deaths heartbreaking disabilities jjpia johnson johnson company dedicated saving lives mothers babies world overthey found equally determined partner breath life almost two years later chinese ministry healths division child health launched neonatal resuscitation program nrp program teaches chinese health care workers rescue newborn baby struggling first full breath life brings together wide range health professionals range local circumstances deliver thousands babies year chinas townships counties cities provinces include obstetricians pediatricians neonatologists anesthesiologists nurses midwives today jjpis help ministry reached across pacific ocean forge partnership american academy wang lixin nurse beijing every day helps mothers pediatrics marini says gold standard bring babies world often years training neonatal asphyxia wonderful international wang lixin seen tragedy unfold baby boy girl fusses collaboration two groups learning much struggles trying take first breath finally turning blue lack oxygen morning wang lixins friend liu jia also nurse like drop ink water since inception july lies upon birthing table past year wang lixin ministry healths nrp trained taught many nurses defeat deathand one native health care professionals trainers holding hand saved lives countless babies would today resolves wang lixin silently today breath otherwise died life prevail came time wang lixins friend first two years program easily surpassed liu jia give birth liu put lifeand childs lifein goal originally set fiveyear mark nrptrained hands nrptrained peer professionals work chinese cities wang lixin nrp national trainer personally taught thanks largely cadre inspiredand inspiringnurses chinese nurses quickly fanned across nation voluntarily nation training one another concentric succession official onechildperfamily drop calligraphers ink falls bowl clear birthing policy heightens water spreads everywhere says may li shanghai every expectant parents based representative jjpi served daytoday dreams anxieties wang contact ministry nrp model working lixin volunteer basis way hardworking nurse sees baby baby traveled deep eastern live instead dying immediately almost help chinas teeming cities get involved program finds give hospital nurses volunteering go anywhere teach anyone feels firstever glimpse professional life greater meaning neonatal rescue trained liu jia son yang yang marini says secret chinas nrp spread health professionals farther faster many initiatives traveled remote outposts show nurses work seen elsewhere asian travels encouragement portable infantsized oxygen tents motivation incredible programs core values helped guide growth nrp nrp task force member keys success found time energy fulfill responsibilities another joy become true soul mates volunteer capacity president division midwives work weve learned much says li chinese nursing association weve others cultural guides forging powerful like wang lixin liu jia proud homelands strong crosspacific collaboration new commitment protect newborn infants preventable wake morning cant believe ive death illness every smile every laugh even every cry lucky work initiative like nrp save precious yang yang future family 're thankful many babies beautiful country says marini trained team knew exactly born may best jobs world breathe first moments life year review consumer health care pch acquisition makes johnson johnson worlds premier consumer health care company groupe vendome acquisition expands global skin care presence new products fuel worldwide growth oral care business seizing rare opportunity pfizer consumer healthcare pch acquisition broadens beyond flosses brushes acquisition pfizer consumer healthcare assets marks important milestone whitening products history worlds comprehensive broadly based health care products company consistent longstanding strategy leadership within attractive health care markets acquisition extends leadership consumer health care categories us also strengthens global reach brings together combination consumer businesses promise sustained growth global basis exus rights nicorette visine nonprescription eyecare products world leader smoking cessation complement vision care franchise gain significant entry highpotential segment lubriderm moisturizing products expand adult skin care franchise combination pfizer listerine antiseptic worlds johnson johnson oral mouthwash transforms oral care neosporin complements care businesses created business billionplus franchise woundcare business expands presence markets billionplus franchise benadryl sudafed expand fourthlargest oral care business otc upperrespiratory business world listerine mouthwash brand nutritionals business continues turn recipes success world johnson johnson holds position way saying thank loyal consumers toothbrushes globally made splenda sucralose americas favorite sweetener new products reach mcneil nutritionals llc introduced official cookbook clean whiten toothbrush splenda world sweetness created response reach inbetween toothbrush enormous consumer demand splenda world position dental sweetness provides families tools create reduced floss including new reach sugar lowercalorie versions favorite foods cleanpaste floss beverages without compromising sweet taste position whitening mcneil nutritionals llc also introduced products introduction splenda brand flavor blends coffee splenda brand quick pack pouches rembrandt whitening strips unsweetened powdered drink mixes viactiv calcium soft chews teens premium mint flavor also new extra strength tylenol bandaid brand compeed cortaid le petit marseillais stayfree dry max carefree large acetaminophen adhesive bandages cold sore patch poison ivy care kit shower gels soaps ultra thin maxi europe gotabs antibiotic bandage europe treatment kit bath hair care products north america us products johnson johnson annual reportjohnsons soothing naturals line expands consumer segment sales company underscores sales major franchise commitment moms sales million growth rate years johnsons baby millions dollars brand indispensable partner baby kids care womens health mom product lines fragrances extended traditional brands online efforts underscored commitment new generation moms johnsons soothing naturals breakthrough collection baby skin care products featuring natural ingredients expanded europe africamiddle east asiapacific regions products combining gentleness johnsons healing power nature first made skin care available us end johnsons baby lotion fragrance extended baby wash cream babycenter wwwbabycentercom redesigned including technology otc advancements enhanced commerce pharmaceuticals nutritionals platform reestablished preeminent online destination moms science leads bath hair care products aveeno skin care products laboratories vendome scientific way growth dermatologicalsolutions innovations evident skin care brand body cleansers new products moisturizers primage clean clear baby toiletries brand oxygenating skincare line skin care business emphasis bringing clean clear growing due strong superior science skin care advantage invisible consumer receptivity evident number acne patch scientific innovations strong new product introductions ambi even clear professional support throughout skin care new line advanced skin increased penetration businesses including care products help women international markets new patented ingredient african latin south line products containing geographic expansion provides strongest asian heritage achieve clear naturally calming active skin care businesses protection available us eventoned skin naturals feverfew enhanced suns harmful uva neutrogena mineral nourishing renewal lotion acquisition rays cause skin cancer sheers pure gentle nourishing care groupe vendome french photoaging see makeup formulated hour moisturizing wash company known adult branded helioplex minerals innovations prompted baby skin care brands technology neutrogena aveeno ultracalming relaunch johnsons le petit marseillais skin care products active shave gel new softlotion line shower gels soaps photobarrier complex aveeno ultracalming softwash adults carefree healthy fresh ky brand ky brand ky brand splenda splenda viactiv calcium liner wash sensual mist touch massage touch massage brand flavor blends brand quick pack soft chews teens asia pacific warming nonwarming warming personal massage lotion line extensions coffee pouches unsweetened mistable lubricant plus personal lubricant powdered drink mixes year review year review pharmaceuticals four new prescription medicines approved new growth platform virology launched important new indications leading rxs inlicensing adds four new products pipeline nearterm pharmaceutical diagnostic strengths pipeline combine new virology franchise communicated june fda granted conditional marketing authorization investment community plans file accelerated approval prezista received european commission secure approval darunavir also known tmc february new molecular entities nmes treatment hivaids nearterm pipeline end four nmesprezista antiretroviral arv experienced virology holds two latestage ionsys jurnista eu adults pharmaceuticals hiv medicines invegawere approved business launched tmc phase iii first fifth doripenem filed first hiv treatment launched investigational nnrti show performance track entire new growth engine virology significant activity patients prior seven additional filings expected business devoted fighting nnrti failure end worlds deadly diseases tmc phase iib dosefinding studies projected filings january launch important new one potent nnrtis ever cns paliperidone virology franchise began four years earlier developed potential palmitate acquisition promising young become backbone range fixeddose carisbamate belgian company tibotecvirco see combinations today tibotec pharmaceuticals ltd tibotec virology franchise also pain tapentadol us therapeutics division ortho biotech earlystage development efforts imid cnto products lp virco bvba backbone complementary inlicensing focused cnto highly innovative virology business hepatitis c hcv tuberculosis tb oncology zarnestra based evolving science combining respiratory syncytial virus rsv pharmaceutical diagnostic approaches first clinical data tmc dacogen eu thanks strong internal development tb patients presented yondelis us capabilities inlicensing important tmc one first potential virology tmc earlystage products virology franchise new tb drugs years telaprevir eu launched strong pipeline emerging profile appears promising growth years come attractive licensing agreement antibacterials doripenem prezista potent protease inhibitor vertex pharmaceuticals ceftobiprole demonstrated significant activity vx called telaprevir added cardiovascular rivaroxaban us wildtype drugresistant promising novel protease inhibitor urology dapoxetine strains hiv experts field agree treatment hcv virology selected eu drug offers new hope treatment pipeline virology franchise hematology ica experienced patients prezista first work close partnership vertex arv decade receive fda accelerated development important est filing est filing approval based phase iib data phase iii molecule commercial rights est filing filed studies early experienced treatment outside us telaprevir currently carisbamate licensed skbio pharmaceuticals naive patients ongoing form part phase iib treatment adults doripenem licensed shionogi co tapentadol licensed grunenthal gmbh yondelis licensed traditional filing within next year chronic hcv hepatitis c blood pharmamar ceftobiprole licensed basilea pharmaceutica rivaroxaban licensed bayer healthcare ica approvals also granted borne liver disease caused infection licensed icagen dacogen licensed mgi pharma canada russia argentina switzerland hepatitis c virus telaprevir licensed vertex pharmaceuticals inc dapoxetine licensed ppdgenupro johnson johnson annual reportorthomcneil inc pharmaceutical segment sales signs deal sales major product worldwide rights sales million growth rate millions dollars two type diabetes risperdal risperdal consta compounds licensing agreement orthomcneil inc procrit metabolex inc eprex yielded two investigational compounds currently clinical development treatment type diabetes orthomcneil secured exclusive world hormonal contraceptives wide development commercialization rights remicade metabolex two compounds represent aciphex pariet novel class insulin sensitizers duragesic inlicensing added topamax fentanyl levaquin transdermal four products rx floxin pipeline details see pages new atypical satisfying unmet needs risperdal consta long adolescents aged years treatment acting injection continues also two antipsychotic schizophrenia perform strongly additional dosage strengths reinforces daily oral medication mostprescribed mg mg specifically designed deliver fastestgrowing treatment risperdal mtab fast leadership paliperidonethe active schizophrenia dissolving form risperdal psychiatry metabolite risperidone risperdal became risperidone made innovative oros first medication available prescription extendedrelease technology approved fda convenient delivery form longstanding leadership demonstrating powerful treatment irritability makes taking medication position diseases efficacy clinically proven associated autistic easy patients central nervous system cns safety tolerability profile disorderincluding dissolves seconds specifically psychiatry longacting formulation symptoms aggression placed tongue strengthened containing paliperidone deliberate selfinjury temper alternative patients fda palmitate tantrums quickly changing difficulty like approval invega far behind moodsin children swallowing pills paliperidone johnson johnson rnai pioneer craig mello named inaugural winner extendedrelease pharmaceutical dr paul janssen award biomedical research tablets new research atypical antipsychotic development llc new award established johnson johnson honor dr paul janssen treatment expects file new one th centurys innovative inspiring pharmaceutical schizophrenia drug application researchers founder janssen pharmaceutica presented important approval paliperidone palmitate inaugural recipient craig c mello phd role discovery rna risperdal risperidone administered injection interference rnai elucidation biological functions dr mello treatment irritability every four weeks professor molecular medicine university massachusetts associated autistic end medical school worcester mass investigator howard disorder meanwhile hughes medical institute shortly thereafter dr mello colleague invega represents risperdal risperidone andrew fire stanford university awarded nobel prize important step forward franchise risperdal physiology medicine discovery year review remicade two new pain medicines granted four significant using novel delivery systems approved indications us two new pain medications skin dose pain relief single approved use delivered minute dose jurnista launched novel drug delivery period ionsys germany denmark systems developed alza first product slovenia slovakia corporation manage incorporate proprietary scheduled launch moderate severe pain etrans iontophoretic european countries ionsys fentanyl transdermal drugdelivery registered iontophoretic transdermal system developed alza marketed janssen remicade infliximab centocor system first needlefree corporation iontophoresis cilag companies throughout inc biologic immune mediated patientactivated analgesic process low world inflammatory disorders garnered four intensity electric field addition significant new us indications generally imperceptible prescription pain medications remicade one worlds patient used approved pricara versatile biologics total nine rapidly transport fentanyl unit orthomcneil inc approved indications ie unique patient across skin biovail corporation populations ranging rheumatoid circulatory system launched ultram er arthritis plaque psoriasis system approved tramadol hci extended approved efficacy claims united states release tablets remicade approved europe expected us first extended us pediatric crohns disease launch second half release tramadol product inhibition progression ionsys indicated market structural damage improved shortterm management looking ahead pain physical function psoriatic arthritis acute postoperative pain jurnista prolonged pipeline johnson johnson treatment chronic severe plaque adult patients requiring release tablets hydro pharmaceutical research psoriasis adults expanded opioid analgesia morphone hcl new development llc maintaining longterm clinical remission hospitalization ionsys prescription treatment hopes file new mucosal healing patients compact selfcontained severe pain developed drug application us moderate severely active system delivers alza corporation tapentadol centrally ulcerative colitis remicade demand pain medication utilizes oros push acting analgesic co global market leader antitnf therapy needed patient pull delivery system developing grunenthal also remicade received patient doubleclicks delivery technology releases plans tapentadol call regulatory approvals four major dosing button system opioid hydromorphone immediaterelease indications european countries delivers preprogrammed consistent rate providing extendedrelease five major new indications dose fentanyl patients hours formulations canada well numerous approvals rest world licensing deals enhance oncology growth engine centocor also two exciting nearterm products cnto nextgeneration antitnf antibody two licensing deals recently ortho biotech products lp also supplemental likely emerge bestinclass enhanced pharmaceuticals growth entered new agreement new drug application doxil product initially studied engine oncology foundation millennium jointly promote velcade combination therapy rheumatoid arthritis psoriatic arthritis procriteprex epoetin alfa usbased physicians treat velcade treat patients ankylosing spondylitis doxil doxorubicin hcl liposome mantle cell lymphoma multiple multiple myeloma whose disease also explored wide range injection deals reinforce myeloma patients received progressed relapsed prior therapeutic areas fully human commitment deliver innovative least one prior therapy therapywas submitted review antibody developed effective treatments cancer patients addition saw janssencilag fda janssen pharmaceutical subcutaneously intravenously unmet medical needs license mgi pharma global kk gained approval velcade administered product long care development commercialization japan dosing intervalsunique class since international rights outside north america nearterm pipeline centocor also developing novel janssencilag businesses marketed dacogen decitabine injection oncology includes two promising immunomodulator cnto leading treatment multiple treatment myelodysplastic drugs yondelis trabectedin firstinclass antiil cnto myeloma velcade bortezomib syndromes mds disease bone codeveloped pharmamar phase iii trials psoriasis novel protease inhibitor marrowwhich currently phase iii subsidiary zeltia group already demonstrated new uses codeveloped trials europe mgi pharma received zarnestra tipifarnib strong efficacy millennium pharmaceuticals inc us approval dacogen may acute myeloid leukemia aml johnson johnson annual report year review medical devices diagnostics new products extend global leadership medical technology six major acquisitions expand key business portfolios cordis corporation portfolio benefits transforming diabetes care acquisitions agreements rd measurement management two strategic acquisitions three licensing transactions strengthened cordis global leadership position lifescan inc focused similarly onetouch interventional cardiology strategic ever moving horizon blood glucose business areas transactions simple blood glucose monitor specifically contributed new product introductions measurement diabetes designed provide greater franchise last year management order access testing developing acquisition ensure medical inc deliver improved patient health markets india privately held company sunnyvale calif develops outcomes currently percent devices postcatheterization closure femoral artery offering patients providers million people expands cordis presence california tools give better insight diabetes monitoring launched accelerated medical ventures stateofthe disease management blood glucose patients art advanced research development facility san onetouch ultra markets require francisco bay area blood glucose monitor simple discrete affordable johnson johnson acquisition helps patients link effects testing offered conor medsystems inc completed february food blood glucose results onetouch horizon monitor expected complement existing drugeluting stent lifescan inc also offers acquisition business unique controlled drugdelivery technology products provide greater animas corporation acquisition provides access blood glucose company specializing cordis portfolio unique drugdelivery monitoring developed insulin delivery systems continued grow addition dozen new technology explored developing markets key development products including across range therapeutic new onetouch ultramini johnson johnson diabetes categories blood glucose monitor franchise lifescan animas cypher select plus first third immediately contributes also marketed onetouch working together provide generation drugeluting stent launched development next ultraeasy countries superior range integrated major global markets except us generation technologies offers basics testing solutions insulin delivery japan aimed advancing small affordable simple blood glucose monitoring carto rmt v niobe integrated standard care touse monitor encourage simplify diabetes control electroanatomical navigation system treatment cardiac appropriate testing greater patients using insulin precise nitinol stent vascular disease glucose control health care professionals angioguard emboli capture distribution front guidewire cordis signed distribution agreement brivant ltd three interventional guidewire products marketed umbrella brand known regatta cordis also signed agreement clearstream technologies group plc distribution rights crescendo ptca percutaneous transluminal coronary angioplasty balloon dilation catheter countries except us japan canada addition biosense webster inc part cordis franchise secured exclusive worldwide rights distribute siemens medical solutions stateoftheart cardiac catheters acuson acunav ultrasound catheters electrophysiologists year review ethicon inc medical devices diagnostics segment sales continues pioneer minimally invasive sales major franchise sales million growth rate surgical advances millions dollars women depuy ethicon ethicon inc introduced two important advances er minimally invasive alternatives ethicon endosurgery common surgeries cordis women gynecaretvt securabove new midurethral sling treat female stress urinary incontinence features smaller mesh implant lifescan skin exit incisions orthoclinical diagnostics gynecare morcellex vision care tissue morcellator facilitates laparoscopic supracervical hysterectomy lsh preserves ethicon endosurgery inc cervix new surgical tool designed minimize launches new surgical innovations challenges physicians face ethicon endosurgery inc mammotome mr bladeless probes performing procedure introduced many surgical innovations targeting sets breast biopsy system gynecare morcellex round portfolio ers new use mri imaging also used facilitate technology nearly every procedure addition advanced sterilization laparoscopic myomectomy performed general bariatric products division ethicon inc procedure uterine gynecological surgeons new products received fda clearance evotech fi broids removed include harmonic wave open shears endoscope cleaner reprocessor ecr ethicons mm latest innovation fi rstever washerdisinfector eliminate acquisition vascular ultrasonic energy open surgery harmonic requirement manual cleaning control systems inc ace open scissor codes contour endoscopes added innovations transtar curved cutter stapler procedure high volume new product womens health portfolio set stapled transanal rectal resection introductions demonstrates ethicon endo primary technology starr echelon endopath stapler surgerys commitment transforming gained uterine artery long endopathxcel bladeless mm patient care innovative medical occlusion treatment bariatric surgery ligamax endoscopic devices minimally invasive open ethicon developing multiple clip applier endopath etsflex surgical procedures lessinvasive treatment articulating endoscopic linear cutter fi broids fi broidrelated symptoms also ethicon introduced ultrapro hernia system uhs surgiflo hemostatic matrix flextip us ethicon omnex surgical sealant europe johnson johnson annual reportdepuy orthopaedics inc evolving minimally invasive vistakon vistakon division techniques sports medicine introduces johnson johnson vision broadens leadership orthomedics south african care inc continues perform new advances acquisitions distributor expands companys strongly around globe vision care presence region new products introduced portfolio development including day acuvue addition depuy capitalized moist brand contact lenses learnings charite day acuvue define artificial disc extended vivid style cosmetic contact strategic acquisitions spine portfolio introduction lenses asian markets internally developed innovations discover cervical disc see story depuy franchise become europe late comprehensive orthopaedics first patients enrolled orthoclinical diagnostics inc receives fda approval business spanning entire us clinical trials july lifetime continuum orthopaedic first bloodscreening test chagas disease carefrom sports medicine early intervention joint replacement spinal fusions chagas disease also called chagas disease three strategic acquisitions american trypanosomiasis first test approved continue broaden depuys infection caused fda use us leadership important category parasite trypanosoma cruzi centers disease impact future development last year two new innovations cruzi damage control prevention meaningful innovations aging hip replacement introduced heart tissue cause death cdc estimates population depuy proxima bone disease endemic million people worldwide hand innovations llc privately preserving hip implant europe countries central infected chagas held manufacturer widely used younger demanding south america well disease fracture fixation products patients depuy asr xl mexico transmission die year chagas disease upper extremities provides leading metalonmetal large head occurs insect bites treated successfully technology plating fastest hip bearings launched blood transfusions detected soon growing underpenetrated us continue gain usage organ transplants via infection occurs segment trauma market see story infected pregnant women cure disease future medical systems sa also depuy mitek saw children utero new entered chronic privately held company use milagro bioreplacable test orthoclinical stage test primarily develops manufactures screw rapidly expand one year diagnostics inc called implemented us due markets arthroscopic fluid postlaunch important indicator ortho cruzi elisa test increased prevalence management systems positions physicians adopting system designed screen blood donors depuy forefront rapidly technology blood donors exposure improve transfusion safety veridex llc introduces second novel diagnostic platform two years orthoclinical diagnostics inc adds new assays menu veridex llc recently advisory panel review claims aid vitros eciq assays include launched second two december monitoring metastatic tests aid diagnosis novel diagnostic platforms first platform breast cancer cellsearch congestive heart failure two years genesearch cellsearch system new genesearch determine whether patient worlds first genebased identifies enumerates breast lymph node diagnostic previous ongoing diagnostic test designed circulating tumor cells ctcs test represent next infection hepatitis detect spread breast directly whole blood chapter invitro diagnostics virus hav quantify levels cancer lymph nodes breast cancer patients see story oncology marker uses molecular technology approved us orthoclinical aid assessment diagnose stage january diagnostic diagnostics inc expanded metabolism new vitros accurately characterize tumors tool identifying diagnostics menus microtip chemistry products used surgery counting ctcs blood new fdaapproved include tests detect guide procedure sample predict progression assays including five assays presence drugs abuse genesearch entered free survival overall vitros eciq measure homocysteine european market mid survival patients immunodiagnostic system concentration blood compliance eu vitro metastatic breast cancer new microtip plasma measure extent medical device regulations cellsearch granted assays vitros fs redblood destruction received favorable fda expanded fdaapproved chemistry system new manage diabetes year review year review caring environment reducing reducing january environmental began new set carbon dioxide fiveyear sustainability impact goals healthy planet emissions goals continue go beyond required growing sales years government johnson johnson family still tracking common johnson johnson taking companies striving environmentalfootprint seriously challenge reduce environmental indicators like water global climate change earning fifth impact operations energy waste applying sustained long products example also going consecutive term actions address total water improve environmental growing threatincluding green power use normalized sales profile products adoption climate decreased percent increase employee leadership award friendly energy policy corresponds environmental literacy taking aggressive percent absolute reduction increase amount johnson johnson measures reduced carbon water use addition paper packaging company earn award dioxide emissions period total waste source sustainably us environmental percent absolute generation normalized managed forests protection agency five basis sales decreased percent full set sustainability consecutive years period sales corresponds goals reviewed participation voluntary increased percent percent absolute reduction wwwjnjcom green power partnership set continue program fosters development trend currently green power market percent electricity partnering partners operate company ranks needs comes green manner consistent thirdlargest corporate power sources solar energy values help purchaser fifthlargest wind energy biomass supply chain partners clearly purchaser us geothermal sources stand expectations external manufacturing developed partnering protect ecosystems continue critical consideration aspect achieving different legal cultural special responsibility johnson johnsons environments leadership growth external manufacturing johnson johnson supports wildlife fund wwf objectives partners operate number nonprofit making environment published standards internationally recognized organizations engaged healthier sensitive responsible external expectations business restoring preserving ecoregions wwf manufacturing ethics product quality labor fragile ecosystems healthy communities healthy standards help us select employment health include conservation ecosystems program external manufacturing safety environment fund trust public improved community health land nature conservancy areas including kenya guiding principles external manufacturers wilderness society mozambique kenya new particularly interested dispensary constructed comply applicable promote safety health community health projects allowing greater access legal requirements wellbeing employees directly link sustainably medicines safe drinking behave ethically operate environmentally managed environment water provided integrity responsible manner need access health care mozambique two new integrate quality implement management communities live near fishing sanctuaries business processes systems ensure ongoing areas high biodiversity created health clinics treat people dignity performance continual signature congo basin staffed respect improvement partnership world equipped johnson johnson annual report year review giving throughout world century giving building health care marked milestone disaster relief philanthropic outreach companys history commemorating th continues today across world reflecting capacity anniversary first documented response credo commitment communities major disaster aftermath live work earthquake struck san francisco highlights many philanthropic efforts johnson johnsonucla provided medical products set took part throughout world management development field hospitals support relief efforts find efforts institute africa instituted program intensive management actions set motion legacy wwwjnjcom training health care keeping mothers health care system leaders east african facilities cameroon china organizations provide hiv children dominican republic india aids prevention treatment care healthy russia zimbabwe support services seventy health leaders seven african project mercys nations trained prematurity prevention medhanealem school initiative us ethiopia provides hospital management partnership march hivaids education training project china dimes kentucky orphan support residents ongoing program department public health uneducated rely equips hospital administrators test whether bundling proven heavily simple conditions management tools interventions lower rates routines survive competencies necessary preventable preterm births support doctors provide quality patient care project mercy ethiopia glen c olsen hospital train everchanging health care elizabeth glaser students public health success national environment administered pediatric aids foundation issues sexually safe kids campaign china hospital management worldwide first partnered transmitted diseases malaria started us association support johnson johnson prevention intestinal seen dramatic decline xianjanssen pharmaceutical ltd prevention parasites educate childhood injury death mothertochild transmission influence villages rate since inception european health leadership hiv pmtct celebrating th anniversary programme europe partnership reached safe kids worldwide safe kids worldwide partnership insead pregnant women fosters multifaceted initiatives active countries johnson johnson hiv testing counseling global scale based major continents brings together participants many countries twoweek providing improving access also continued educational experience equips relief help communities health care concepts tools disaster strikes southern us affected health products techniques strategies play hurricane katrina significant leadership roles efforts included assistance mebendazole donation health care responded products establishing mental initiative cameroon money following health programs new multiyear program associacao saude de several major disasters children traumatized provide mebendazole familia brazil trains outreach including mudslides disaster funding treatment intestinal workers provide hivaids philippines automatic electronic worms health education female earthquake indonesia defibrillators key severely infected adolescents adult women several johnson johnson community health centers children world partners dozens affiliates provided local new orleans support million doses health teams assistance immediate several universities distributed use trained nearly aftermath disasters educational services cameroon women benefited year review board directors first row left right william c weldon chairman board directors chief executive officer christine poon vice chairman board directors michael e johns md executive vice president health affairs emory university chief executive officer robert w woodruff health sciences center emory university chairman emory healthcare emory university second row left right ann jordan former director social services department chicago lyingin hospital leo f mullin retired chairman chief executive officer delta air lines inc mary sue coleman phd president university michigan third row left right david satcher md phd director center excellence health disparities morehouse school medicine former us surgeon general susan l lindquist phd member former director whitehead institute biomedical research professor biology massachusetts institute technology steven reinemund executive chairman pepsico inc fourth row left right james g cullen retired president chief operating officer bell atlantic corporation arnold g langbo retired chairman chief executive officer kellogg company charles prince chairman chief executive officer citigroup inc johnson johnson annual reportcommittees nomination corporate governance nominating corporate governance committee board comprised entirely independent directors responsible overseeing corporate governance matters reviewing possible candidates board membership recommending nominees election committee also responsible overseeing process performance evaluations board committees additionally committee reviews companys management succession plans executive resources audit audit committee comprised entirely independent ann jordan chairman directors helps board oversee companys accounting james g cullen reporting practices recommends independent public arnold g langbo accountants appointment board reviews charles prince performance monitors adequacy internal accounting steven reinemund practices procedures controls reviews significant changes accounting policies public policy james g cullen chairman public policy advisory committee reviews companys mary sue coleman phd policies programs practices public health issues leo f mullin regarding environment health safety employees committee also reviews companys governmental affairs policies public policy compensation benefits issues facing company committee advises makes compensation benefits committee comprised recommendations board issues appropriate entirely independent directors reviews compensa public policy advisory committee comprised tion philosophy policies nonboard management independent directors companys general counsel compensation committee respect executive vice presidents corporate affairs government compensation perquisites compensation matters affairs policy employees except members executive committee committee also administers companys leo f mullin chairman longterm incentive plans determines compensation russell c deyo members executive committee additionally thomas gorrie phd committee oversees management various susan l lindquist phd retirement pension longterm incentive savings health brian perkins welfare plans cover substantially employees david satcher md ph companys domestic operations employees certain international subsidiaries science technology arnold g langbo chairman science technology advisory committee comprised michael e johns md independent directors companys vice president ann jordan science technology advises board scientific charles prince matters including major internal projects interaction steven reinemund academic outside research organizations acquisition technologies products finance david satcher md phd chairman finance committee exercises management authority mary sue coleman phd board intervals board meetings michael e johns md finance committee comprised chairman susan l lindquist phd presiding director vice chairman board theodore j torphy phd william c weldon chairman james g cullen christine poon board directors committees board corporate officers william c weldon thomas gorrie phd theodore j torphy phd chairman board directors vice president vice president chief executive officer government affairs policy science technology chairman executive committee joann heffernan heisen nicholas j valeriani christine poon vice president diversity worldwide chairman vice chairman board directors medical devices diagnostics group executive committee david p holveck executive committee vice president dominic j caruso corporate development vice president finance chief financial officer raymond c jordan executive committee executive committee vice president public affairs johnson johnson principal corporate communications management group responsible stephen j cosgrove operations allocation corporate controller john papa resources company treasurer committee oversees laverne h council coordinates activities vice president chief brian perkins consumer pharmaceuticals information officer vice president medical devices corporate affairs diagnostics business segments russell c deyo subsidiary within vice president general counsel steven rosenberg business segments chief compliance officer secretary exceptions managed citizens executive committee assistant general counsel country located kaye fostercheek joseph c scodari vice president human resources worldwide chairman executive committee pharmaceuticals group executive committee colleen goggins worldwide chairman ajit shetty johnson johnson consumer group vice president executive committee worldwide operations company group chairmen rick anderson john h johnson kristine peterson supratim bose guy j lebeau md marc e robinson donald casey karen licitra jose v sartarelli phd rosemary crane sheri mccoy michael e sneed roy n davis julie h mchugh pericles p stamatiades seth h z fischer patrick mutchler paul stoffels md carlos gottschalk david norton johnson johnson annual reportcorporate governance managements responsibility johnson johnson governed values set forth pricewaterhousecoopers llp independent registered credo created general robert wood johnson public accountingfirm engaged perform integrated audit principles guided us years continue set consolidated financial statements internal control tone integrity theentire company levels financial reporting report independent registered employees johnson johnson committed tothe ethical public accountingfirm onpage principles embodied credo principles theaudit committee board directors composed woven fabric company solely independent directors financial knowledge thevalues articulated credo extend account experience provide appropriate oversight review internal ing financial responsibilities johnson johnson share control matters key accountingand financial reporting issues holders investors management johnson audit committee regular basis addition johnson responsible theintegrity objectivity independent auditors general counsel vice presi accompanying financial statements related information dent internal audit regularly meet private sessions also responsible ensuringthat financial data reported audit committee discuss results work including accurately manner facilitates understanding observations adequacy internal financial controls thisdata quality financial reporting confirmation prop evidence commitmentto responsibility erly discharging responsibilities relevant matters maintain welldesigned system internal accountingcon executive committee continuously involved trols encourage strong effective corporate governance thereview financial results well developing board directors continuously review business results standing strategies key initiatives longterm growth strategic choices focus financial stewardship intentis ensure maintain objectivity business corporate staff professionallytrained internal audi assessments constructively challenge approachto business torswho travel worldwide monitor system internal opportunities issues monitor business results accounting controls designed provide reasonable assurance related controls assets safeguarded transactions events consolidated financial statements financial data recorded properly internal controls include selfassessments follow prepared conformity accounting internal reviews operating companies principles generally accepted united states america company continuedto invest significant include amounts based upon best judgments time resources order ensure compliance section committed present discuss results operations sarbanesoxley act based work per clear transparent manner order provide timely com formed concluded internal control finan prehensive understandable information shareholders cial reporting effective december refer managements report internal control financial reporting require management teams operating companies certify compliance policy william c weldon dominic j caruso business conduct systematic program designed chairman board vice president finance ensure compliance policies view policy directors chief chief financial officer onbusiness conduct please visit website executive officer wwwjnjcomourcompanypolicies table contents managements discussion analysis audited consolidated financial statements organization business segments consolidated balance sheets results operations consolidated statements earnings analysis sales business segments consolidated statements equity analysis consolidated earnings provision consolidated statements cash flows fortaxes income notes consolidated financial statements liquidity capital resources managements report internal control information financialreporting cautionary factors may affect future results report independent registered public accountingfirm summary operations statistical data shareholder return performance graphs reconciliation nongaap financial measures johnson johnson annual report managements discussion analysis results operations financial condition organization business segments acceptance companys consumer products involves signif icantexpenditures advertising andpromotion description company business segments johnson johnson subsidiaries company managements objectives approximately employees worldwide engaged primary objective company achieve superior levels research development manufacture sale broad range capital efficient profitablegrowth accomplishthis products health care field company conducts busi companys management operates business consistent ness virtually countries world primary focus certain strategic principles proven successful products related human health wellbeing time end company participates growth areas thecompany organized three business segments human health care committed attaining leadership consumer pharmaceutical medical devices diagnos positions growth segments developmentof tics theconsumer segment includes abroad range products innovative products services new products introduced used baby kids care skin care oralcare woundcare within past five years accounted sales womens health care fields well nutritional billion sales invested research thecounter pharmaceutical products theseproducts mar development increase billion keted principally general public sold increase reflects managements commitmentto importance wholesalers directly independentand chain retail outlets ongoingdevelopment new anddifferentiated products throughout world thepharmaceutical segment includes services sustain longterm growth products thefollowing therapeutic areas antifungal anti operating companies located infective cardiovascular contraceptive dermatology gastroin countries thecompany views principle decentralized man testinal hematology immunology neurology oncology pain agement asset fundamental success broadly management psychotropic central nervous system urology based business also fosters entrepreneurial spirit combin virology areas theseproducts distributed directly ing extensive resources large organization retailers wholesalers health care professionals prescrip ability react quickly local market changes challenges tion use general public themedical devices diag thecompany committed developing global business nostics segment includes broad range ofproducts used leaders drive growth objectives businesses man principally professional fields byphysicians nurses thera aged thelong term order sustain leadership positions pists hospitals diagnostic laboratories clinics theseprod achieve growth provides enduring source value ucts includecordis circulatory disease management products shareholders depuys orthopaedic joint reconstruction andspinal care prod unifying management team companys dedi ucts ethicons woundcare womens health products cated employees achieving objectives credo ethicon endosurgerys minimally invasive surgical products credo provides common set values serves constant lifescans blood glucose monitoring andinsulin delivery reminder companys responsibilities customers products orthoclinical diagnostics professional diagnostic employees communities andshareholders thecompany products andvision cares disposable contact lenses believes basic principles along itsoverall mission thecompanys structure based upon principle improving quality life peopleeverywhere enable decentralized management theexecutive committee johnson johnson continue beamong leaders johnson johnson principalmanagement group respon health care industry sible theoperations allocation resources company committee oversees coordinates activi ties consumer pharmaceutical medical devices results operations diagnostics business segments subsidiary within analysis consolidated sales business segments exceptions managed worldwide sales increased billion com citizens country located pared increases product lines company competes sales increases consisted following companies large small located throughout world competition strong product lines without regard sales increase due thenumber andsize competing companies involved com volume petition inresearch involvingthe development improve price ment ofnew existing products andprocesses particularly currency significant thedevelopment new improved products total important companys success areas business also includes protecting companys portfolio intellec sales us companies billion billion tual property thecompetitive environment requires substantial billion represents increase investments continuingresearch multiple sales forces sales inter inaddition development maintenance customer national companies billion billion billion represents increase johnson johnson annual reportus estimated fiscal fourth quarter growth rate international sales enhanced approximately year approximately years thenet earnings impact theadditional week billions dollars wasnegligible us international sales segment inbillions dollars consumer pharmaceutical medical devices anddiagnostics thefiveyear compound annual growth rates worldwide us international sales respectively thetenyear compound annual growth rates worldwide us international sales respectively analysis sales business sales segments geographic region consumer segment consumer segment sales billion increase inbillions dollars operational growth accountingfor us total growth due positive currency fluctua europe westernhemisphere tions us consumer segment sales billion excludingus increase international sales billion asia pacific africa increase result operations due currency fluctuations consumer segment sales growth led strongsales performance skin care baby kids carefranchises overthecounter otc pharma ceuticals nutritionals franchise sales billion international geographic regions experienced sales increase growth led success growth consistingof europe relaunch tylenolupper respiratory product western hemisphere excluding us asia line products containingphenylephrine instead pseu pacific africa regions thesesales increases include impact doephedrine well growth splendano calorie sweet currency fluctuations us dollar foreign eners partially offset sales declines adult currencies positive impacts europe analgesics theskin care franchise sales bil thewestern hemisphere excluding us negative lion representing increase impact asiapacific africa region attributable sales growth aveeno johnsons company acustomer adult suncare newly acquired groupe vendme adult represented total revenues sales skin care product lines thebaby kids care franchise sales cardinal health mckesson accounted grew billion stronggrowth led total revenues respectively success ofpowder product lines international markets results benefited inclusion rd week well cleanser lotion cream product lines us see note annual closing date details thecompany major consumer franchise sales change dollars millions vs vs otc pharmaceuticals nutritionals skin care baby kids care womens health total managements discussion analysis results operations financial condition international markets thewomens health franchise sales thetreatment irritability associated autistic disorder grew billion resulting solid contri children adolescents risperdalcompound patent butions kyand stayfreeproduct lines sales scheduled expire us december company franchises grew billion submitted pediatric data fda order extend exclu primarily due acquisition rembrandtbrand sivity june expiration product patent oral care products typically results loss market exclusivity result theoperating results consumer healthcare business significant reduction sales acquired pfizer inc december reported procritepoetin alfa eprexepoetin alfa companys financial statements beginning combined sales billion decline com results subsequent acquisition date notsignificant pared prior year procritexperienced sales decline consumer segment sales billion dueto competitors anticompetitive contracting strategy increase operational growth accounting oncology clinics eprexsales increased total growth due positive currency approval weekly administration recent restora fluctuations us consumer segment sales billion tion thelabel subcutaneous administration eprexin anincrease international sales billion europe resulted volumegains although eprexpatent increase result operations expired mostmajor european markets erythropoietin prod due currency fluctuations uct approved using biosimilar regulatory pathway consumer segment sales billion increase several companies made filings using pathway operational growth accounting forof filings review thecompany predict total growth due positive currency impact us products may beapproved sales increased international sales increased remicadeinfliximab biologic approved due operational gains positive currency treatment crohns disease ankylosing spondylitis psoriatic impact arthritis ulcerative colitis use thetreatment rheumatoid arthritis achieved sales billion growth pharmaceutical segment prior year continued growth driven increased pharmaceutical segment sales billion demand due expanded indications fiscal third increase change due quarter remicadereceived fda approval operational growth remaining increase related treatment adults chronic severe plaque psoriasis positive impact currency us pharmaceutical segment topamaxtopiramate approved sales billion increase international adjunctive monotherapy use epilepsy well pharmaceutical segment sales billion increase prophylactic treatment migraines achieved billion included operational growth sales increase prior year themigraine related thepositive impact currency indication key driver sales growth risperdalrisperidone medication treats levaquinlevofloxacin floxinofloxacin symptoms schizophrenia bipolar mania risperdal achieved combined sales billion representing constarisperidone long acting injection treats growth prior year growth achieved despite symptoms schizophrenia achieved billion sales lack growth market increase prior year sales growth wasposi duragesicfentanyl transdermal fentanyl transdermal tively impacted lower rebates risperdaland higher system sales declined billion reduction demand risperdalconsta us sales risperdal decline resultof impactof generic andrisperdalconstaincreased billion competition theus certain international markets generic whileinternational sales increased billion competition us began january october company received approval us thehormonal contraceptive franchise sales declined food drug administration fda market risperdalfor billion reduction ortho major pharmaceutical product revenues change dollars millions vs vs risperdalrisperidonerisperdalconstarisperidone procriteprexepoetin alfa remicadeinfliximab topamaxtopiramate levaquinfloxinlevofloxacinofloxacin duragesicfentanyl transdermal fentanyl transdermal system aciphexparietrabeprazole sodium hormonal contraceptives total johnson johnson annual reportevranorelgestrominethinyl estradiol first contraceptive pharmaceutical segment sales billion patch approved fda experienced significant decline increase change due sales result labeling changes negative media coverage operational growth remaining increase related concerning product safety thesales decline also result positive impact currency us pharmaceutical segment continued generic competition oral contraceptives growth sales decreased international pharmaceutical seg ortho tricyclenlo norgestimateethinyl estradiol ment sales increased included operational low dose oral contraceptive partially offset sales decline growth related thepositive impact currency hormonal contraceptive franchise pharmaceutical segment sales billion concertamethylphenidate hcl product increase due operational treatment attention deficit hyperactivity disorder achieved growth due positive currency fluctuations us sales billion representing increase pharmaceutical segmentsales increased inter although original concertapatent expired national pharmaceutical segment sales grew two new concertapatents issued included operational growth related expire present fda notapproved generic positive impact currency version substitutable concerta abbreviated new pharmaceutical segment sales included drug applications andas generic versions concerta benefit adjustments related previously estimated perform pending may approved time ance based rebate allowances managed care contractsthese natrecornesiritide product thetreatment adjustments less salesin patients withacutely decompensated congestive heart failure dyspnea rest minimal activity experi medicaldevicesand diagnostics segment enced significant decline demand due negative media cov themedical devices diagnostics segment achieved sales erage regarding meta analysis selected historical clinical billion representing increase prior trials thecompany believes data support year operational growth negative conclusions medical consumer publications impact currency us sales billion currently approved label natrecorreflects available increase international sales billion data date increase operations negative natrecorwas purchased company currencyimpact resulted recording intangible asset depuy franchise achieved billion sales amortized years remaining unamortized intangible increase prior year growth prima value associated natrecorwas billion endofthe rily due depuys orthopaedic joint reconstruction products fiscal fourth quarter based current estimate mitek sports medicine products trauma business projected future cash flows adjustment intangible asset acquisitions future medical systems sa hand innovations required company currently conducting several clinical llc also contributed growth trials natrecor outcomes predicted cordis franchise achieved sales billion may impact projections future cash flows increase sales cyphersirolimuselut company received fda approval ingstent largest product cordis franchise relatively prezistadarunavir antihiv medication invega flat relatively modest growth cyphersirolimuseluting paliperidone extendedrelease tablets new atypical antipsy stent sales caused lower average selling prices negative chotic thetreatment schizophrenia additionally media regulatory focus concerning drug eluting stents ionsysfentanyl iontophoretic transdermal system first corresponding lack market growth strong needlefree patientactivated analgesic system received fda performances biosense webster endovascular busi european commission approval jurnistaprolonged nesses fiscal third quarter com release tablets hydromorphone hcl anew prescription treat pany received fda approval market precisenitinol stent ment severepain received approval european angioguardemboli capture guidewire treat mutual recognition procedure carotid artery disease addition thecompany received ce mark major medical devices diagnostics franchise sales change dollars millions vs vs depuy cordis ethicon endosurgery ethicon lifescan vision care orthoclinical diagnostics total prior year amounts restated conform current presentation managements discussion analysis results operations financial condition approval europefor cypher selectsirolimuseluting medical devices diagnostics segment stent usein treatment severe arterial disease leg achieved sales billion representing increase april july cordis cardiology division prior year operational growth posi cordis corporation received warning letters fda tive impact currency us sales increased regarding good manufacturing practice regulations good international sales increased clinical practice regulations response warning letters operations currency cordis made improvements quality systems provided periodic updates fda theclinical warning analysis consolidated earnings letter issues resolved fdas satisfaction provision fortaxes income respect thequality system warning letter addition improvement updates cordis juarez mexico stent sup consolidated earnings provision fortaxes income plier locations inspected acceptable results thefda increased billion billion earned inspected miami site global quality system includ theincrease billion ing design control system august acceptable percent sales consolidated earnings results cordis received observations fda provision fortaxes income inspection thefda inspections completed cordis llc improvement change percent insan german puerto rico cordis laboratory operations sales improvement warren new jersey january thereby completingall sections follow highlight scheduled follow inspections cordis process significant components changes consolidated earnings evaluating reviewing overall results inspections provision taxes income fda cost products sold selling marketing andadministra theethicon endosurgery franchise achieved sales tive expensescost products sold selling marketingand billion increase major administrative expenses percent sales asfollows contributor growth continues beendocutter sales include products usedin performing bariatric procedures sales thetreatment obesity important focus area thefran cost products sold chise strong results achieved success percent point increasedecrease harmonic scalpel ultrasonic cutting coagulating prior year surgical device received approval january selling marketing administrative expanded indications include plastic surgery also expenses stronggrowth advanced sterilization products percent point increasedecrease theethicon franchise sales grew reaching prior year billion result solid growth mesh womens health urology products sales increase percent sales costof gynecareproducts anddermabondhad strong results products sold due unfavorable product mix higher also continued growth suture sales manufacturing costs pharmaceutical consumer seg thelifescan franchise achieved billion salesin ments decrease percent sales selling mar increase animas corporation keting administrative expenses result acquired fiscal first quarter provided lifescan leveraging selling expenses reduction advertising platform entry insulin pump segment promotional spending company continuedto diabetes market key contributor growth strong focus controllingexpenses performance also achieved onetouchultra decrease percent sales cost product line us international markets ofproducts sold due lower manufacturing costs pri sales thevision care franchise reached billion marily related cyphersirolimuselutingstent well growth rate prior year growth asongoingcostcontainmentactivity across organization led global success acuvueoasysbrand contact partially offset negative impact pharmaceutical product lenses hydraclearplus acuvueadvance mix also decrease percent sales selling astigmatism international success day marketing administrative expenses due cost acuvuemoistand acuvuedefine containment initiatives pharmaceutical segmentpartially theorthoclinical diagnostics franchise achieved bil offset increases investment spending medical lion sales increase growth devices diagnostics segment achieved clinical laboratory immunohematology sales decrease percent sales cost us international markets ofproducts sold due favorable mix well cost themedical devices diagnostics segment achieved improvement initiatives also decrease per sales billion representing increase cent sales selling marketing administrative expenses prior year operational growth posi due companys focus managingexpenses tive impact currency us sales increased partially offset increase investment spending across international sales increased oper number businesses focused driving future growth ations currency johnson johnson annual reportresearch developmentresearch development activi molecules accounted million tax iprd ties represent significant part companys business charges wasincluded operating profit pharmaceuti theseexpenditures relate development new products cal segment closure medical corporation company expert improvement existing products technical support products ise intellectual property biosurgicals market accounted compliance governmental regulations theprotection million tax iprd charges wasincluded consumers patients worldwide costs research activi operating profit medical devices diagnosticsseg ties excluding inprocess research development charges ment peninsula pharmaceuticals inc abiopharmaceutical com follows pany focused developingand commercializing antibiotics treat lifethreatening infectionsaccounted million tax dollars millions iprd charges wasincluded operating profit research development expense pharmaceutical segment million tax iprd charge percent increase prior year related scott lab inc referred wasincluded oper percent sales ating profit medical devices diagnosticssegment company recorded iprd charges research development expense percent sales million tax result acquisition us commer pharmaceutical segment cial rightsto certain patents knowhow field combinedresearch development sedation analgesia scott lab inc charge expense percent sales theconsumer andmedical included operating profitof medical devices devices diagnostics segments diagnostics segment respectively research development activities accelerated income expense netother income expense net pharmaceutical segment increasing billion includes gains losses related sale writedown thecompound annual growth rate approximately ofcertain investments equity securities held johnson thefiveyear period since johnson development corporation gains losses dis theincreased investment research developmentin posal property plant equipment currency gains losses segments demonstrates companys focus knowledge minority interests litigation settlements liabilities royalty based products andreflects significant number projects income change income expense net inlate stage development increase income million income expense net included gain inprocess research developmentin company associated guidant acquisition agreement termination recorded inprocess research developmentiprd charges fee less associated expenses million income million taxrelated acquisitions expense net also included royalty incomepartially offset consumerhealthcare business pfizer inc vascular control expenses associated recording additional product lia systems inc ensure medical inc colbar lifescience ltd hand bility reserves theintegration costs associated innovationsllc future medical systems sa consumer acquisition pfizer consumer healthcare healthcare business pfizer inc accounted million income expense net included royalty taxofthe iprd chargesand included operating incomepartially offset several expense items none profit consumersegment iprd chargesforall individually significant following acquisitions included operating profit income expense net included several medical devices diagnostics segment vascular controlsys expense items none individually significant tems inc privately held company focused developing med partially offset royalty income ical devicesto treat fibroids controlbleeding obstetric gynecologic applications accounted million tax operating profit segment iprd chargesensure medical inca privately held com operating profits segment business follows pany develops devicesforpostcatheterization closure femoral artery accounted million taxofthe iprd percent chargescolbar lifescience ltd privately held company special segment sales dollars millions izing reconstructive medicine tissue engineering accounted consumer million taxofthe iprd charges hand innovations pharmaceutical llc privately held manufacturer fracture fixation products upper extremities accounted million taxofthe med devices diag iprd chargesfuture medical systems sa privately held segments total company primarily develops manufacturesand markets less incomeexpenses arthroscopic fluid management systems accounted million allocated taxofthe iprd charges segments company recorded iprdcharges million earnings tax related acquisitions oftransform pharmaceuticals provision taxes inc closure medical corporation peninsula pharmaceuticals inc income international commercial rights certain patents amounts allocated segments include interest incomeexpense minority knowhow fieldof sedation analgesia scott lab inc interest general corporate incomeexpense transform pharmaceuticals inc company specializing dis covery superior formulations novelcrystalline forms drug managements discussion analysis results operations financial condition operatingprofit interest income increased million due bysegment primarily higher rates interest well higher average inbillions dollars cash balance cash balance including current marketable securities billion end averaged consumer billionascompared billion average cash balance pharmaceutical medical devices interest expense decreased compared anddiagnostics due part decrease average debt balance billion billion provision taxes incometheworldwide effective income tax rate tax rate benefited reversal tax allowances million associated tibotec business partially consumer segmentconsumer segment operating profit offset guidant acquisition agreement termination fee decreased percent sales recorded rate theeffective taxrate included operating profitdeclinedto resulting million abenefit million due reversal tax liability pre iprd expenses well expenses associated pfizer viously recorded fiscal fourth quarter related consumer healthcare integration recorded con technical correction americanjobs creation act sumer segment operating profit increased prior year percent sales operating profit increased slightly despite increases investment liquidity capital resources spending advertising research development cash flows pharmaceutical segmentin pharmaceutical segment cash flow fromoperations billion increase operating profit increased percent sales billion theincrease cash generated increased increase result million operations result net incomeincrease billion iprd recorded partially offset increases net noncash impact iprd charges themajor changes research development spending lower gross margins assets liabilities billion increase accounts pharmaceutical segment operating profit payable accrued liabilities partially offset billion decreased percent sales declined increase deferred taxes billion increase change primarily due increased current noncurrent assets investment research development spending well net cash used investing activities increased bil theimpact million iprd expenses lion primarily due billion increase acquisi tion activity occurred late fiscal fourth medical devices diagnostics segmentin oper quarter detailed discussion mergers acquisi ating profit themedical devices diagnostics segment tions see note also billion net decrease increased percent sales increased sales ofinvestments capital expenditures billion theprimary driver improved operating profit billion billion respectively guidant acquisition agreement termination fee less associated net cash used financing activities increased bil expenses million recorded par lion due billion used common tially offset increases iprd charges addition advertis stockrepurchase program publicly announced ingandpromotional expense leveraging offset part march completed earlyin fiscal fourth quarter increases research development spending partially offset billion net proceeds medical devices diagnostics segment short term debt operating profit increased percent sales cash currentmarketable securities billion increased increase driven atthe end compared billion end improved gross margins due cost reduction programs primarily due acquisition consumer product mix primarily related thecyphersirolimuseluting healthcare business pfizer inc december stent partially offset increased investment cash generated operations amounted billion research development spending billion cash generated interest income expenseinterest income increased operations billion themajor factors contributing million due primarily higher rates interest well increase net incomeincrease billion net higher average cash balance despite billion common noncash impact iprd charges billion decrease stock repurchase program increase acquisition activity inother current noncurrent assets also contributed cash balance including current marketable securities increase partially offset billion decrease billion end averaged billion accounts payable accrued liabilities additionally cash pay compared billion average cash balance ments approximately billion made previously interest expense increased slightly compared accrued taxes repatriation undistributed international due higher average debt balance billion earnings accordance american jobs creation act billion partially offset also increase approximately billion decrease interest rates pension fundingin compared johnson johnson annual reportoper net debt billion compared net cash billion total debt represented total capitalshare p pe holders equity total debt total capital billions dollars shareholders equity per share endof ial ndi r compared yearend increase rain lo theperiod ended december material cash commitments johnson johnson continues beone industrial companies triple credit rating summary borrowings found note longterm contractualobligations andcommitments thecompany longterm contractual obligations primarily financing market risk lease debt obligations unfunded retirement plans thecompany uses financial instruments manage impact significant obligations satisfy theseobligations foreign exchange rate changes cash flows accordingly company use cash operations thefollowing table thecompany enters forward foreign exchange contracts summarizes companys contractual obligations protect value certain foreign currency assets liabilities aggregate maturities december see notes hedge future foreign currency products costs gains details losses contracts offset gains losses onthe longterm unfunded underlyingtransactions appreciation us dollar operating debt retirement december market rates wouldincrease dollars millions leases obligations plans total unrealized value companys forward contracts million conversely depreciation us dollar december market rates woulddecrease theunrealized value companys forward contracts million either scenario gain loss forward contract wouldbe offset gain loss underlying transaction therefore wouldhave impact future total earnings cash flows thecompany hedges exposure fluctuations cur amounts include interest expense rency exchange rates effect certain assets liabili ties foreign currency entering currency swap contracts share repurchase dividends change spread us foreign interest march company announced board rates companys interest rate sensitive financial instru directors approved stock repurchase programauthorizing ments would either increase decrease unrealized value company buy back billion companys com companys swap contracts approximately million monstock program completed early fiscal fourth either scenario maturity gain loss swap contract quarter million shares repurchased addition wouldbe offset gain loss underlying transaction thecompany annual program repurchase shares therefore wouldhave impact future cash flows use employee stock incentive plans thecompany enter financial instruments thecompany increased dividend th fortrading speculative purposes company consecutive year cash dividends paid per share policy entering contracts parties compared dividends per share least equivalent credit rating thecounterparties per share thedividends distributed contracts major financial institutions follows significant concentration exposure one counter party management believes risk loss remote first quarter total unused credit available company approximates second quarter billion including billion credit commitments ofwhich billion expire september billion third quarter expire october billion expire september fourth quarter also included billion uncommitted lines total various banks worldwide expire totalborrowings end january board directors declared regular cash billion billion respectively increase borrowings dividend per share payable march share resultof financingthe acquisition holders record february company expects consumerhealthcare business pfizer incin december continue practice paying regular cash dividends net debt cash current marketable securities managements discussion analysis results operations financial condition information tables show progression accrued rebates returns promotions reserve doubtful accounts critical accounting policies estimates reserve cash discounts segment business theyears managements discussion analysis results operations ended december january financial condition based companys consolidated financial statements prepared accordance consumer segment accountingprinciples generally accepted us theprepara tion financial statements requires management balance balance make estimates assumptions affect amounts beginning payments end dollars millions period accruals period reported revenues expenses assets liabilities related disclosures actual results may may differ estimates thecompany believes understanding accrued rebates certain key accountingpolicies estimates essential accrued returns achieving insight companys operating results accrued promotions financial condition thesekey accountingpolicies include rev subtotal enue recognition incometaxes legal self insurance contin reserve doubtful accounts gencies valuation longlived assets assumptions used reserve cash discounts determine amounts recorded forpensions total employee benefitplans accountingfor stock options revenue recognitionthecompany recognizes revenue accrued rebates product sales goods shipped delivered title accrued returns risk loss pass customer provisions certain rebates accrued promotions sales incentives trade promotions coupons product returns subtotal discounts customers accounted reductions sales reserve doubtful accounts thesame period related sales recorded product discounts granted based terms reserve cash discounts arrangements direct indirect market participants total well market conditions includingprices charged com includes reserve customerrebates million december petitors rebates largest medicaid rebate provi million january recorded contra asset sion estimated based sales terms historical experience trend analysis projected market conditions various pharmaceutical segment markets servedthecompany evaluates market conditions balance balance products groups products primarily analysis beginning payments end wholesaler third party sellthrough market dollars millions period accruals period research data well internally generated information sales returns generally estimated recorded based accrued rebates onhistorical sales returns information products exhibit accrued returns unusual sales return patterns due dating competition accrued promotions orother marketing matters specifically investigated subtotal analyzed part accountingfor sales return accruals reserve doubtful accounts sales returns allowances represent reserve products reserve cash discounts may returned due expiration destruction field specific areas product recall thereturns reserve based total historical return trends product market percent gross sales accrued rebates promotional programssuch product listing allowances accrued returns cooperative advertising arrangements recorded accrued promotions year incurred continuingpromotional programs include subtotal coupons andvolumebased sales incentive programs redemption cost consumer coupons based historical reserve doubtful accounts redemption experience product value volumebased reserve cash discounts incentive programs derived estimating sales volumes total incentive period recorded products sold includes reserve customerrebates million december reasonablylikely changes assumptions used calculate million january recorded contra asset accruals rebates returns promotions antici includes million related previously estimated performancebased rebate pated amaterial effect financial statements allowances managed care contracts company currently discloses impact changes assump tions thequarterly annual filing financial statement impact johnson johnson annual reportmedicaldevicesand diagnostics segment insurers recovery probable appropriate reserves receivables recorded estimated amounts balance balance may collected third partyinsurers beginning payments end dollars millions period accruals period longlivedand intangible assetsthecompany assesses changes economic conditions andmakes assumptions regard accrued rebates ing estimated future cash flows evaluating value accrued returns companys property plant equipment goodwill intangi accrued promotions ble assets assumptions estimates may change subtotal time itmay may necessary thecompany reserve doubtful accounts record impairment charges reserve cash discounts employee benefit plansthecompany sponsors various retire total ment pension plans including defined benefit defined con tribution termination indemnity plans cover accrued rebates employees worldwide plans based assumptions discount rate expected return plan assets expected accrued returns salary increases health care cost trend rates see note accrued promotions detail rates effect rate change would subtotal companys results operations thecompany reserve doubtful accounts adopted sfas employers accounting defined pension reserve cash discounts postretirement plans amendment fasb state total ments rthis statement requires recognition fundedstatus benefit plan state includes reserve customerrebates million december million january recorded contra asset ment financial position changes funded status theyear changes occur recognized company also earns service revenue copromotion cer comprehensive incomeoci net tax tain products years presented service revenues less stock optionsduring fiscal first quarter com total revenues included salestocustomers pany adopted sfas rshare based paymentthecom income taxesincometaxes recorded based amounts pany applied modified retrospective transition method refundable payable thecurrent year include results implement sfas r previously reported financial state difference us gaap accountingandus tax ments restated accordance provisions reporting recorded deferred tax assetsor liabilities thecom sfas r see note information regarding pany estimates deferred tax assetsand liabilities based cur stock options rent tax regulations rates changes tax laws rates may affect recorded deferred tax assets liabilities future newaccounting standards management believes changes estimates wouldnot december financial accountingstandards board result material effecton thecompanys results operations fasb issued sfas rshare based payment state cash flows financial position ment establishes standards accountingfor transactions company repatriated billion undistrib entity exchanges equity instruments goods uted international earnings accordance american services focuses primarily accountingfor transactions jobs creation act ajca recorded tax charge entity obtains employee services sharebased pay million thefiscal fourth quarter ment transactions employee stock options fiscal second quarter company recorded taxben restricted stock units thestatement requires measurement efitof million due reversal tax liability previ cost employee services received exchange ously recorded fiscal fourth quarter award equity instruments employee stock options associated technical correction made ajca may restricted stock units fair value grant date atdecember january cumula cost recognized period tive amount undistributed international earnings approx employee required provide services exchange imately billion billion respectively thecompany award requisite service period thecompany adopted intends continue reinvest undistributed international statement fiscal first quarter applying modi earnings expand international operations therefore us fied retrospective transition method previously reported finan tax expense recorded cover undistributed por cial statements restated reflect adoption tion intended forrepatriation sfas r legaland selfinsurance contingenciesthecompany records accruals various contingencies including legal proceedings product liability cases arise normal course business theaccruals based managements judgment probability losses opinions legal counsel applicable actuarially determined estimates additionally company records insurance receivable amounts third party managements discussion analysis results operations financial condition thecompany implemented sfas inventory costs economic market factors amendment arb thefiscal first quarter johnson johnson aware products used environ adoption statement amaterial effect ment whereformore decade policymakers consumers companys results operations cash flows financial position businesses expressed concerns abouttherising cost health june fasb issued fasb interpretation fin carein response concerns johnson johnson long accounting uncertainty income taxes interpretation standing policy pricing products responsibly forthe period fasb statement interpretation prescribes recog united statesthe weighted average compound annual nition threshold measurement attribute financial growth rate ofjohnson johnson net price increases forhealth care statement recognition measurement tax position taken products prescription overthecounter drugshospitalandpro expected taken tax return theinterpretation also fessional products us consumerpriceindex cpi provides guidance derecognition classification inflation rates even though moderate many parts matters fin effective thefiscal year worldduring continue effect worldwide company adopt accordingly thecompany assessing economies consequently way companies operate impact adoption fin currently inthe face increasing costs company strives maintain believe adoption material effect results profit margins cost reduction programs productivity operations cash flows financial position improvements periodic price increases thecompany september fasb issued statement financial facesvarious worldwide health care changes may result accounting standards fair value measurementsthis inpricing pressures include health care costcontainment statement defines fair value establishes framework measur government legislation relating sales promotions ing fair valuein generally accepted accounting principles andreimbursement expands disclosures fair valuemeasurements state thecompany also operates environment ment effective fiscal first quarter com becomeincreasingly hostileto intellectual property rights pany adopt thestatement time company believes generic drugfirms filed abbreviated new drug applica adoption sfas material effect tions seeking market generic forms companys results operations cash flows financial position key pharmaceutical products prior expiration applicable september fasb issued statement financial patents covering products event company accountingstandards employers accounting defined successful defending patent claims challenged abbrevi pensionand postretirement plans amendment fasb ated new drug application filings generic firms statements rthis statement requires introduce generic versions product issue resulting recognition fundedstatus benefit plan state potential substantial market share revenue losses ment financial position also requires recognition product information see thediscussion liti component comprehensive incomeoci net tax gation filers abbreviated newdrug applications gains losses prior service costs credits arise note period butare recognized components net periodic benefit cost pursuant statements legal proceedings statement also new provisions regarding measurement thecompany involved numerous product liability cases date well certain disclosure requirements thestatement united states many concern adverse reactions effective fiscal year end company adopted drugs medical devices thedamages claimed substan statement time tial company confident adequacy september sec issued staff accounting thewarnings instructions use accompany bulletin sab expresses staffs views regarding products feasible predictthe ultimate outcomeof process quantifying financial statement misstatements litigation however company believes liability thebulletin effective fiscal year end theimple results cases willbe substantially covered mentation bulletin impact companys existing amounts accrued companys balance sheet results operations cash flows financial position underitsselfinsurance program third party product thefollowing accountingpronouncements became liability insurance effective nothave material impact thecompany also involved anumber patent trade companys results operations cash flows financial position mark lawsuits incidental business theultimate fin accounting conditional asset retirement legal financial liability company respect obligations interpretation fasb statement claims lawsuits proceedings referred sfas exchanges nonmonetary assets amendment estimated certainty however companys opin apb ion based examination matters experience thefollowing accountingpronouncements became effective todate discussions counsel theultimate outcome material impact companys results oflegal proceedings net liabilities already accrued operations cash flows financial position companys balance sheet expected material eitf issue whether investor apply equity adverse effect companys financial position although method accounting investments common stock theresolution reporting period one eitf issue accounting preexisting relationships matters couldhave significantimpact companys results parties business combination operations cash flows period see note information regarding legal proceedings johnson johnson annual reportcommon stock market prices thecompanys common stock listed new york stock exchange symbol jnj thecomposite market price ranges johnson johnson common stock high low high low first quarter second quarter third quarter fourth quarter yearend close cautionary factors may affect future results annual report contains forwardlooking statements forwardlooking statements relate strictly historical orcurrent facts anticipate results based managements plans subject uncertainty forwardlooking state ments may identified use words like plans expects anticipates estimates words similar meaning conjunction amongotherthings discus sions future operations financial performance companys strategyfor growth product development regulatory approval market position expenditures forwardlooking statements based current expecta tions future events thecompany guarantee anyforwardlooking statement accurate although company believes ithas reasonable expectations assumptions investors realize underlying assumptions prove inaccurate unknown risks uncer tainties materialize actual results couldvary materially companys expectations projections investors therefore cautioned place undue reliance forwardlooking statements thecompany undertake update wardlooking statements result new information future events developments risks uncertainties include general industry conditions competition economic conditions interest rate currency exchange rate fluctuations technological advances new products andpatents attained competitors challenges inherent new product development including obtaining regu latory approvals challenges patents us foreign health care reforms andgovernmental laws regulations trends toward health care costcontainment increased scrutiny health care industry government agencies product efficacy safety concerns resulting product recalls regulatory action thecompanys report theyear ended december includes exhibit discussion additional factors couldcause actual results differ expectations thecompany notes factors permitted bythe private securities litigation reform act managements discussion analysis results operations financial condition consolidated balance sheets johnson johnson subsidiaries december january dollars millions except share per share data note assets current assets cash cash equivalents notes marketable securities notes accounts receivable trade less allowances doubtful accounts inventories notes deferred taxes incomenote prepaid expenses receivables total current assets marketable securities noncurrent notes property plant equipment net notes intangible assets net notes goodwill net notes deferred taxes incomenote assets note total assets liabilities shareholders equity current liabilities loans andnotes payable note accounts payable accrued liabilities accrued rebates returns promotions accrued salaries wages commissions accrued taxes income total current liabilities longterm debt note deferred taxes incomenote employee related obligations notes liabilities total liabilities shareholders equity preferred stockwithout par value authorized unissued shares common stockpar value per share note authorized shares issued shares accumulated comprehensive incomenote retained earnings less common stock held treasury cost note shares shares total shareholders equity total liabilities shareholders equity see notes consolidated financial statements johnson johnson annual reportconsolidated statements earnings johnson johnson subsidiaries dollars millions except per share figures note sales customers cost products sold gross profit selling marketing administrative expenses research expense purchased inprocess research development note interest income interest expense net portion capitalized note income expense net earnings provision taxes income provision taxes incomenote net earnings basic net earningspershare notes diluted net earnings per share notes sseeee nnootteess ttoo ccoonnssoolliiddaatteedd ffiinnaanncciiaall ssttaatteemmeennttss consolidated financial statements consolidated statements equity johnson johnson subsidiaries note receivable accumulated employee treasury comprehensive retained stock ownership comprehensive common stock stock dollars millions note total income earnings plan esop income issued amount amount balance december net earnings cash dividendspaid employee stock compensation stock option plans conversion subordinated debentures repurchase common stock comprehensive income net tax currency translation adjustment unrealized gains securities employee benefit plans gains derivatives hedges reclassification adjustment total comprehensive income note receivable esop balance january net earnings cash dividendspaid employee stock compensation stock option plans conversion subordinated debentures repurchase common stock comprehensive income net tax currency translation adjustment unrealized losses securities employee benefit plans gains derivatives hedges reclassification adjustment total comprehensive income note receivable esop balance january net earnings cash dividendspaid employee compensation stock option plans conversion subordinated debentures repurchase common stock comprehensive income net tax currency translation adjustment unrealized losses securities employee benefit plans losses derivatives hedges reclassification adjustment total comprehensive income balance december see notes consolidated financial statements johnson johnson annual reportconsolidated statements cash flows johnson johnson subsidiaries dollars millions note cash flows operating activities net earnings adjustments reconcilenet earnings cash flows depreciation andamortization property intangibles stock basedcompensation purchased inprocess research development deferred tax provision accounts receivable allowances changes assets liabilities net effects fromacquisitions increase accounts receivable increasedecrease inventories increasedecrease accounts payable accrued liabilities increasedecrease current noncurrent assets increase current noncurrent liabilities net cash flows operating activities cash flows investing activities additions property plant equipment proceeds disposal assets acquisitions net cash acquired note purchases ofinvestments sales investments primarily intangibles net cash used investing activities cash flows financingactivities dividends shareholders repurchase common stock proceeds shortterm debt retirement shortterm debt proceeds longterm debt retirement longterm debt proceeds exercise stock optionsexcess tax benefits net cash used financing activities effect exchange rate changes cash cash equivalents decreaseincrease cash cash equivalents cash cash equivalents beginning year note cash cash equivalents endof year note supplemental cash flow data cash paid year interest incometaxes supplemental schedule noncash investing financing activities treasury stock issued employee compensation stock option plans net cash proceeds conversion debt acquisitions fair value assets acquired fair value liabilities assumed net cash paid acquisitions sseeee nnootteess ttoo ccoonnssoolliiddaatteedd ffiinnaanncciiaall ssttaatteemmeennttss consolidated financial statements notes consolidated financial statements summary significant accounting policies applying modified retrospective transition method principles consolidation previously reported financial statements restated theconsolidated financial statements include accounts reflect adoption sfas r see note johnson johnson subsidiaries thecompany inter company implemented sfas inventory costs company accounts transactions eliminated anamendmentof arb fiscal first quarter adoption statement material effect description company business segments companys results operations cash flows financial position thecompany approximately employees worldwide june fasb issued fasb interpretation fin engaged research development manufacture sale accounting uncertainty income taxes interpretation abroad range products thehealth care field thecom fasb statement interpretation prescribes recog pany conducts business virtually countries world nition threshold measurement attribute financial itsprimary focus products related human health statement recognition measurement tax position taken andwellbeing expected taken tax return theinterpretation also thecompany organized three business segments provides guidance derecognition classification consumer pharmaceutical medical devices diagnos matters fin effective thefiscal year tics theconsumer segment manufactures markets broad company adopt accordingly thecompany assessing range products usedin baby kids care skin care impact adoption fin currently believe oralcare woundcare womens health care fields well adoption material effect results nutritional overthecounter pharmaceutical products operations cash flows financial position theseproducts marketed principally general public september fasb issued statement financial sold wholesalers directly independentand accounting standards fair value measurementsthis chain retail outlets throughout world thepharmaceutical statement defines fair value establishes framework measur segment includes products thefollowing therapeutic areas ing fair valuein generally accepted accounting principles antifungal antiinfective cardiovascular contraceptive derma expands disclosures fair valuemeasurements state tology gastrointestinal hematology immunology neurology ment effective fiscal first quarter com oncology pain management psychotropic central nervous sys pany adopt thestatement time company believes tem urology virology areas theseproducts distributed adoption sfas material effect directly retailers wholesalers health care professionals results operations cash flows financial position prescription use general public themedical devices september fasb issued statement financial diagnostics segment includes broad range ofproducts used accountingstandards employers accounting defined principally professional fields byphysicians nurses thera pensionand postretirement plans amendment fasb pists hospitals diagnostic laboratories clinics theseprod statements rthis statement requires ucts includecordis circulatory disease management products recognition fundedstatus benefit plan state depuys orthopaedic joint reconstruction andspinal care prod ment financial position also requires recognition ucts ethicons woundcare womens health products component comprehensive incomeoci net tax ethicon endosurgerys minimally invasive surgical products gains losses prior service costs credits arise lifescans blood glucose monitoring andinsulin delivery period butare recognized components net products orthoclinical diagnostics professional diagnostic periodic benefit cost pursuant statements products andvision cares disposable contact lenses statement also new provisions regarding measurement date well certain disclosure requirements thestatement newaccounting pronouncements effective fiscal year end company adopted december fasb issued sfas rshare statement time see note based paymentthis statement establishes standards september sec issued staff accounting accountingfor transactions entity exchanges bulletin sab expresses staffs views regarding equity instruments goods andservices focuses primarily process quantifying financial statement misstatements accountingfor transactions entity obtains thebulletin effective fiscal year end theimple employee services sharebased payment transactions mentation bulletin impact companys employee stock options restricted stock units thestate results operations cash flows financial position ment requires measurement cost employee services thefollowing accountingpronouncements became received exchange award equity instruments effective nothave material impact employee stock options restricted stock units fair value companys results operations cash flows financial position grant date cost recognized period fin accounting conditional asset retirement employee required provide services obligations interpretation fasb statement exchange award requisite service period thecom sfas exchanges nonmonetary assets amendment pany adopted statement fiscal first quarter apb johnson johnson annual reportthe following accounting pronouncements became effective products groups products primarily analysis material impact companys wholesaler third party sellthrough market results operations cash flows financial position research data well internally generated information eitf issue whether investor apply equity sales returns generally estimated recorded based method accounting investments common stock historicalsales returns information products exhibit eitf issue accounting preexisting relationships unusual sales returnpatterns due dating competition parties business combination marketing matters specifically investigated analyzed aspart ofthe accounting forsales returnaccruals sales returns cash equivalents allowancesrepresent reserve products may bereturned thecompany considers securities maturities three due expiration destruction field specific areas prod months less purchased becashequivalents uct recall returns reserve based historicalreturn trends product market percent togross sales investments promotional programssuch product listing allowances shortterm marketable securities carried cost cooperative advertising arrangements recorded approximates fair value investments classified availablefor year incurred continuingpromotional programs include sale carried estimated fair value unrealized gains coupons andvolumebased sales incentive programs losses recorded component accumulated compre redemption cost consumer coupons based historical hensive income longterm debt securities company redemption experience product value volumebased ability intent hold maturity carried amortized incentive programs based estimated sales volumes cost also approximates fair value management determines incentive period recorded products sold appropriate classification investment debt equity company also earns service revenue copromotion certain securities time purchase reevaluates determi products andincludes sales tocustomers nation balance sheet date thecompany periodically reviews investments equity securities impairment shipping handling adjusts investments fair value decline shipping handling costs incurred million mil market value deemed otherthan temporary lion million respectively included selling marketing administrative expense property plant equipment depreciation amount revenue received shipping andhandling less property plant equipment stated cost sales customers periods presented companyutilizes straightline methodof depreciation overthe estimated useful lives assets inventories inventories stated lower cost market determined building building equipment years firstin firstout method land leasehold improvements years machinery equipment years goodwill intangible assets effective beginningof fiscal year accordance thecompany capitalizes certain computer software sfas company discontinuedthe amortization relat development costs included machinery andequipment ing existing goodwill indefinite lived intangible assets incurred connection developing orobtainingcomputer nonamortizable sfas requires thatgoodwill software internal use capitalized software costs amor nonamortizable intangible assets assessed annually tized estimated useful lives ofthe software impairment thecompany completed annual impairment generally range years test thefiscal fourth quarter impairment thecompany reviews longlived assets assess recover determined future impairment tests beperformed annually ability using undiscounted cash flows necessary charges thefiscal fourth quarter sooner triggering eventoccurs impairments longlived assets recorded theamount intangible assets finite useful lives continue bywhich present value future cash flows less amortized useful lives reviewed impair carrying value assets ment warranted economic conditions see note details intangible assets revenue recognition thecompany recognizes revenue product sales goods shipped delivered title riskof loss pass financial instruments thecompany follows provisions sfas accounting customer provisions certain rebates sales incentives derivative instruments hedging activitiesas amended trade promotions product returns discounts customers sfasno requires derivative instruments recorded accounted reductions sales inthe period balance sheet fair value changes fair value related sales recorded derivatives recorded period current earnings product discounts granted based terms comprehensive income depending whether thederivative arrangements direct indirect market participants designated part hedge transaction ifso type well market conditions includingprices charged com hedge transaction petitors rebates largest medicaid rebate provi sion estimated based sales terms historical experience trend analysis projected market conditions various markets servedthecompany evaluates market conditions notes consolidated financial statements company uses forward exchange contracts manage advertising exposure variability cash flows primarily related costs associated advertising expensed year incurred theforeign exchange rate changes future intercompany prod included selling marketing administrative uct third party purchases raw materials denominated expenses advertising expenses worldwide arecomprised foreign currency company also uses currency swaps man television radio print media internetadvertising bil age currency risk primarily related borrowings lion billion billion types derivatives designated cash flow hedges addition ally thecompany uses forward exchange contracts tooffset income taxes exposure certain foreign currency assets liabilities thecompany intends continue reinvest undistributed forward exchange contracts designated hedges international earnings expand international operations therefore changes fair values derivatives therefore us tax expense recorded cover recognized earningsthereby offsetting current earnings undistributed portion intended forrepatriation atdecember effect related foreign currency assets andliabilities andjanuary cumulative amount undis designation cash flow hedge made entrance tributed international earnings approximately billion date derivative contractat inception derivatives billion respectively expected highly effective changes fair valueof deferred incometaxes recognized tax consequences derivative designated cash flow hedgeand highly oftemporary differences applying enacted statutory taxrates effective recorded accumulated othercomprehensive applicable future years differences thefinancial income underlying transactionaffects earnings reporting tax basis existing assets andliabilities reclassified earnings account hedged transaction fair valueof derivative instrument ie forward net earnings per share foreign exchange contract currency swap aggregation basic earnings per share computed dividing net earnings currency future cash flows discounted present valueat available common shareholders weighted average prevailingmarket interest rates subsequently converted number common shares outstanding theperiod diluted theus dollar current spot foreign exchange rate earnings per share reflects potential dilution thatcouldoccur ongoing basis company assesses whether securities exercised converted common stock derivative continues behighly effective offsetting changes using treasury stock method thecashflows hedged items derivative isno longer expected behighly effective hedge accountingisdis use estimates continued hedge ineffectiveness included current preparation consolidated financial statements period earnings insignificant conformity accounting principles generally accepted company documents relationships hedged us requires management make estimates assumptions items derivatives overall risk management strategy affect amounts reported estimates used includes reasons undertakinghedge transactions entering accounting sales discounts rebates allowances incen derivatives objectives strategy minimize tives product liabilities income taxes depreciation amortization foreign currency exposures impact companys financial employee benefits contingencies intangible asset liabil performance protect companys cash flow adverse ity valuations instance determining annual pension movements foreign exchange rates ensure appropriate postemployment benefit costs company estimates rate ness financial instrumentsand manage enterprise risk return plan assetsand cost future health care bene associated financialinstitutions fits actual results may may differ estimates product liability annualclosing date accruals product liability claims recorded undis thecompany follows concept fiscal year ends onthe counted basis itis probable liability incurred sunday nearestto theend month december normally amount liability reasonably estimated based fiscal year consists weeks every five orsix years existing informationthe accruals adjusted periodically fiscal year consists weeks case additional information becomes available resultof cost availability factors effective november company inventories ceased purchasing third party product liability insurance based end inventories comprised theavailability prior coverage receivables insurance recover ies related product liability claims recorded onanundis dollars millions counted basis itis probable thata recovery realized raw materials supplies goods process research development finished goods research development expenses expensed incurred upfront andmilestone payments made third parties con nection research development collaborations expensed incurred point regulatory approval pay ments made third parties subsequent regulatory approval capitalized amortized remaining useful life related product amounts capitalized suchpayments included intangibles net accumulated amortization johnson johnson annual report property plant equipment borrowings end property plant equipment thecomponents longterm debt follows costand accumulated depreciation effective effective dollars millions dollars millions rate rate land land improvements zero coupon convertible subordinated buildings building equipment debentures due machinery equipment debentures due construction progress debentures due notes due less accumulated depreciation debentures due notes due industrial revenue bonds thecompany capitalizes interest expense part cost construction facilities equipment interest expense capi talized million million less current portion million respectively depreciation expense including amortization capital ized interest billion bil weighted average effective rate lion billion respectively upon retirement disposal property plant equip company access substantialsources funds ment cost related amount accumulated depreciation numerous banks worldwide total unused creditavailable oramortization eliminated asset accumulated company approximates billion including billion depreciation accounts respectively difference creditcommitments billion expire september net asset value proceeds recorded inearnings billion expire october billion expire september also included billion uncommitted lines various banks worldwide expire rental expense lease commitments interestcharged borrowings credit rentals space vehicles manufacturing equipment line agreements based either bids provided banks officeand data processing equipment operating leases prime rate london interbank offered rates libor plus approximately million million applicable margins commitment fees agreementare million material theapproximate minimum rental payments required thecompany filed shelf registration securities operating leases initial remaining noncancelable exchange commission sec became effective novem lease terms excess one year december ber enables company issue bil lion debt securities warrants purchase debt securities dollars millions total debt issued full amount remained available december july alza completed private offering commitments capitalleases significant zero coupon convertible subordinated debentures issued price per principal amount employee related obligations maturity december outstanding debentures end employee related obligations total principal amount maturity million yield maturity per annum computed semiannual dollars millions bond equivalent basis periodic interest payments pension benefits terms debentures holders entitledto postretirement benefits convert debentures approximately million shares postemployment benefits johnson johnson stock price per share deferred compensation approximately million shares issued decem ber due voluntary conversions note holders less current benefits payable option holder debentures may repurchased company july purchase price employee related obligations equal issue price plus accreted original issue discount purchase date thecompany option may elect prepaid employee related obligations million deliver either johnson johnson common stock cash million respectively included combination stock andcash eventof repurchase ofthe assets consolidated balance sheet prepaid debentures thecompany option may also redeem employee related obligations decreased significantly debentures july issue due implementation sfas notes consolidated financial statements price plus accreted original issue discount december goodwillas december january allo january fair value based quoted market cated segment business follows value debentures million med dev million respectively dollars millions consumer pharm diag total shortterm borrowings current portion long term goodwill debtamounted billion end january billion raised commercial paper program acquisitions theremainder represents principally local borrowing translationother international subsidiaries goodwill aggregate maturities longterm obligations commencing january acquisitions translationother dollars millions goodwill december certain business relationships theweighted average amortization periods patents member companys board directors chief trademarks intangible assets years years executive officer major bank bank provided ser respectively theamortization expense amortizable intangible vices thecompany including providing line credit assets thefiscal years ended december january payments made significant either january million million company bank million taxrespectively certain patents intan gibles written fair value fiscal years resulting charge included amortiza intangible assets goodwill tion expense theestimated amortization expense thefive end gross net amounts succeeding years approximates million taxper year intangible assets goodwill substantially amortization expense included cost dollars millions products sold trademarks nonamortizablegross less accumulated amortization income taxes trademarks nonamortizablenet theprovision taxes incomeconsists patents trademarksgross less accumulated amortization dollars millions currently payable patents trademarksnet us taxes intangiblesgross international taxes less accumulated amortization intangiblesnet deferred subtotal intangible assetsgross us taxes less accumulated amortization international taxes subtotal intangible assetsnet goodwillgross less accumulated amortization goodwillnet total intangible assets goodwillgross less accumulated amortization total intangible assets goodwillnet johnson johnson annual reporta comparison incometax expense federal statutory rate international currency translation companys effective tax fortranslation subsidiaries operating nonus dollar curren rate follows cies company determined thatthe local currencies international subsidiaries functional currencies except dollars millions highly inflationary economies defined us compound cumulative rates inflation international past three years substantial portion earnings taxes cash flows local currency income consolidating international subsidiaries balance sheet tax rates currencyeffects recorded component accumulated statutory comprehensive income equity account includes puerto rico results translating balance sheet assets liabilities ireland operations current exchange rates except located highly infla research orphan drug taxcredits tionary economies reflected operating results us state local analysis changes international subsidiaries foreign currency translation adjustments included note excluding ireland net currency transaction translation gains losses repatriation included income expense net losses international earnings million million million iprd respectively effective tax rate common stockstock option plans stockcompensation agreements company hadsubsidiaries operating puerto rico stock options various tax incentive grants also theus possessions tax credit december company stockbased com expired applies certain operations puerto pensation plans theshares outstanding contracts rico addition company subsidiaries manufacturing companys stock option plans ireland incentive tax rate increase tax longterm incentive plan stock compensation plan rate mainlydue reversal atax liability million nonemployee directors plan centocor inno reported tax provision resulted technical vasive devices alza inverness scios stock option plans correction american jobs creationact options restricted stock granted partiallyoffset benefit reported forthe reversal tax plans exceptthe longterm incentive plan allowances million associated tibotec business thecompensation cost recorded sfas r temporary differences carry forwards charged incomefor plans asfollows million million million thetotal incometax benefit recognized income deferred tax deferred tax statement share based compensation costs million dollars millions asset liability asset liability million million employee related obligations share based compensation costs capitalized part inventory insignificant periods stock based compensation stock options expire years date grant depreciation vest service periods range six months five nondeductible intangibles years options granted currentmarket price international rd capitalized dateof grant longterm incentive plan tax company may issue million shares common stock reserves liabilities shares available future grants longterm income reported tax purposes incentive plan million endof miscellaneous international thecompany settles employee stock option exercises capitalized intangibles treasury shares treasury shares replenished throughout miscellaneous us year thenumber shares used settle employee stock total deferred income taxes option exercises thedifference net deferred tax incomeper thebalance sheet net deferred tax included taxes incomeon balance sheet notes consolidated financial statements fair value option award estimated date summary option activity plan december grant using blackscholes option valuation model uses january january changes assumptions noted following table starting years ending dates presented expected volatility represents blended rate year daily weighted aggregate historicalaverage volatility rate week average implied outstanding average intrinsic volatility rate based atthemoney traded johnson johnson shares thousands shares exercise price value options life years prior expected volatility shares december wasbased year weekly historical volatility rate historical options granted data isused determine expected life option options exercised riskfree rate based us treasury yield curve effect options canceledforfeited atthe time grant shares january theaverage fair value options granted thefair value options granted estimated based weighted average assumptions options exercised options canceledforfeited shares january riskfree rate expected volatility options granted expected life yrs yrs yrs options exercised dividendyield options canceledforfeited shares december thetotal intrinsic value options exercised million million million respec tively thetotal unrecognized compensation cost million december million january million january theweighted average period cost berecognized years years years thefollowing table summarizes stock options outstanding exercisable december shares thousandsoutstanding exercisable average average exercise average exercise exercise price range options life price options price average contractual life remaining years stock options exercisable january january summary stock activity plan average price average december life years options average price outstanding average life years respectively shares thousands shares shares january restricted stock units stock granted company grants restricted stockunits avesting periodof stock issued three years company settles employee stockissuance stock canceledforfeited treasury sharestreasury sharesare replenished throughout year forthe number ofsharesused foremployee stockissuances shares december average fair value restricted stock units granted using fair marketvalue date ofgrant fair value restricted stock units discounted fordividends paid restricted stock units vesting periodthe fair value sharesissued million johnson johnson annual report segments businessand geographic areas sales customers dollars millions consumerunited states international total pharmaceuticalunited states international total medical devices diagnosticsunited states international total worldwide total operating profit identifiable assets dollars millions consumer pharmaceutical medical devices diagnostics segments total less incomeexpenses allocated segments general corporate worldwide total additions property depreciation plant equipment amortization dollars millions consumer pharmaceutical medical devices diagnostics segments total general corporate worldwide total sales customers longlived assets dollars millions united states europe western hemisphere excluding us asiapacific africa segments total general corporate non longlived assets worldwide total see note description segments company operates export sales intersegment sales significant thecompany customer represented ormore total revenues sales top distributors accounted total revenues amounts allocated segments include interest incomeexpense minority interest general corporate incomeexpense general corporate includes cash marketable securities includes million million inprocess research development iprd consumerand medical devices diagnostics segments respectively medical devices diagnostics segment also includes guidant acquisition agreement termination fee less associated expenses million includes million million iprd pharmaceutical medical devices diagnostics segmentsrespectively includes million iprd medical devices diagnostics segment longlived assetsinclude property plant equipment net respectively intangible assets net respectively notes consolidated financial statements accumulated comprehensive income tax effecton unrealized gainslosses equity components comprehensive incomeloss consist securities balance expense million million following million respectively tax effectrelated employee benefit plans million million total thetax effecton gainslosses derivativesand unrealized gains accumulated foreign gains losses hedges losses million million currency losses employee derivatives comprehensive benefit million see note foradditional dollars millions translation securities benefit plans hedges incomeloss information relating derivatives hedging dec thecurrency translation adjustments currently changes adjusted incometaxes relate permanent net change due investments international subsidiaries hedging transactions net amount reclassed net earnings pensions benefit plans net changes thecompany sponsors various retirement pension plansincludingdefined benefit defined contribution jan termination indemnity plans cover employees changes worldwide thecompany also provides postretirement bene net change due fitsprimarily health care insurance us retired employees hedging transactions theirdependents net amount reclassed many international employees covered government net earnings sponsored programs thedirect cost company net changes isnotsignificant jan retirement plan benefits primarily based changes employees compensation last three five years net change due retirement number years service interna hedging transactions tional subsidiaries plans funds deposited net amount reclassed trustees annuities purchased group contracts net earnings reserves provided net changes thecompany fund retiree health care benefits dec advance right modify plans future thecompany uses date consolidated financial total comprehensive incomefor includes reclassifi statements december january respec cation adjustment gains million realized saleof tively measurement date us international equity securities associated tax expense million retirement benefitplans total comprehensive incomefor includes reclassifi september fasb issued statement financial cation adjustment gains million realized saleof accounting standards employers accounting defined equity securities associated tax expense million benefit pension postretirement plans amendment total comprehensive incomefor includes reclassifi fasb statements rwhich requires cation adjustment gains million realized saleof employer fully recognize overfunded underfunded sta equity securities associated tax expense million tus pension postretirement benefit plans asset liability financial statements addition com pany required recognize component compre hensive income loss actuarial gains losses prior service costs credits arise duringtheperiod immediately recognized components net periodic benefit cost theincremental effect applying sfas bil lion reduction shareholders equity netof deferred taxes johnson johnson annual reportnet periodicbenefit cost thecompanys defined benefit retirement plans benefit plans includedthe following components retirement plans benefit plans dollars millions service cost interest cost expected return plan assets amortization prior service cost amortization net transition asset recognized actuarial losses curtailments settlements net periodic benefit cost thenet periodic benefit cost attributable us retirement plans amounts expected berecognized net periodic cost million million mil coming year thecompanys defined benefit retirement lion plans postretirement plans dollars millions amortization net actuarial loss amortization prior service cost amortization net transition obligation theweightedaverage assumptions following table represent rates used develop actuarial present value pro jected benefit obligation theyear listed also net periodic benefit cost thefollowing year retirement plans benefit plans dollars millions us benefit plans discount rate expected longterm rate return plan assets rate increase compensation levels international benefit plans discount rate expected longterm rate return plan assets rate increase compensation levels companys discount rates determined consideringcurrent thefollowing table displays assumed health care cost yield curves representing high quality longterm fixed income instru trend rates individuals ments resulting discount rates consistentwith duration health care plans plan liabilities health care cost trend rate assumed next year theexpected longterm rate return plan assets rate cost trend rate assumed assumptions determined using building block approach con declineultimate trend sidering historical averages real returns asset class year rate reaches ultimate trend rate incertain countries historical returns meaningful consideration given local market expectations longtermreturns onepercentagepoint change assumed health care cost trend rates wouldhave following effect onepercentage onepercentage dollars millions point increase point decrease health care plans total interest service cost postretirement benefit obligation notes consolidated financial statements thefollowing table sets forth information related thebenefit obligation fair value plan assets yearend thecompanys defined benefit retirement plans postretirement plans retirement plans benefit plans dollars millions change benefit obligation projected benefit obligationbeginning year service costs interest costs plan participant contributions amendments actuarial gainslosses divestitures acquisitions curtailments settlements benefits paid plan effect exchange rates projected benefit obligationend year change plan assets plan assets fair valuebeginning year actual return plan assets company contributions plan participant contributions divestitures acquisitions curtailments settlements benefits paid plan assets effect exchange rates plan assets fair valueend year funded status end year unrecognized actuarial losses unrecognized prior service costs unrecognized net transition assets total recognized consolidated balance sheet amounts recognized companys balance sheet consist following adoption sfas book accruals prepaid benefits intangible assets accumulated comprehensive income total recognized consolidated balance sheet adoption sfas noncurrent assets current liabilities noncurrent liabilities total recognized consolidated balance sheet amounts recognized accumulated comprehensive income consist net actuarial losses prior service costscredits unrecognized net transition assets total tax effects change accumulated comprehensive income due adoption sfas tax effects accumulated benefit obligations end year includes post employment benefits perthe adoption sfas johnson johnson annual reportstrategic asset allocations determined country based considered nonmature plans longterm strategic asset nature liabilities considering thedemographic allocations consistent types plans emphasis composition plan participants average age years ser placed diversifying equities abroadbasis combinedwith vice active versus retiree status thecompanys plans currencymatching fixed incomeassets thefollowing table displays projected future benefitpayments companys retirement benefit plans dollars millions projected future benefit payments retirement plans benefit plansgross medicare rebates benefit plansnet thecompany required fund us retirement plans appropriate meet longterm obligations plans required anticipate funding certain countries united states funding meet minimum statutory fundingrequirements interna pension plans nota common practice funding provides tional plans funded accordance local regulations economic benefit consequently company several additional discretionary contributions made deemed pension plans notfunded thefollowing table displays projected future minimum contributions companys us international unfunded retirement plans amounts include discretionary contributions company may elect make future dollars millions projected future contributions unfunded us retirement plans unfunded international retirement plans thecompanys retirement plan asset allocation december january target allocations follows percent target plan assets allocation us retirement plans equity securities debt securities total plan assets international retirement plans equity securities debt securities real estate total plan assets thecompanys benefit plans unfunded except us plans accumulated benefit obligations excess plan life insurance contract assets million million assets consist following december january respectively thefair value johnson johnson common stock directly retirement plans dollars millions held planassets million total plan assets accumulated benefit obligation million total plan assets december projected benefit obligation january respectively plan assets fair value notes consolidated financial statements cash cash equivalents marketable securities december january amortized unrealized estimated amortized unrealized estimated dollars millions cost gainslosses fair value cost gainslosses fair value current investments cash government securities obligations corporate debt securities money market funds time deposits total cash cash equivalents current marketable securities noncurrent investments marketable securities financial instruments orequivalent credit rating average investments thecompany follows provisions sfas requiring mature within six months company incurred derivative instruments recorded balance sheet related losses fair value december balance deferred net gains savings plan derivatives included accumulated comprehensive income million aftertax company expects substantially thecompany voluntary k savings plans designed thisamount reclassified earnings overthe next enhance existing retirement programs covering eligible monthsas result transactionsthat expected occur employees thecompany matches percentage thatperiodthe maximum lengthof time overwhich company employees contributions consistent provisions hedging transaction exposure months amount ulti plan heshe eligible mately realized earnings differ foreign exchange rates us salaried plan onethird change realized gains losses ultimately determined company match waspaid company stock employee actual exchange rates maturity thederivative derivative stock ownership plan esop unless employee choseto gainslosses initially reported component compre redirect investment establish esop hensive income reclassified earnings period company loaned million esop trust purchase forecasted transaction affects earnings shares company stock open market exchange forthe years ended december january company received note balance wasrecorded january net impact hedge ineffectiveness transac reduction shareholders equity remainingshares held tions qualifying forhedge accounting discontinuance esop trust allocated participant accounts endof hedgesto companys financial statements insignificant february march going forward com refer note disclosures movements accumu pany match made cash follows individual employees lated comprehensive income investment elections total company contributions plans million million million concentration credit risk thecompany invests excess cash deposits major banks throughout worldand high quality money market instruments thecompany policy making investments onlywith commercial institutions least johnson johnson annual report mergers acquisitions divestitures thefollowing table presents preliminaryallocation certain businesses acquired billion cash purchase price related consumer healthcare business billion liabilities assumed acquisitions pfizer inc date acquisition accounted purchase method accordingly dollars millions results operations included financial state current assets ments respective dates acquisitions except property plant equipment notedbelow goodwill december company completed acquisition consumer healthcare business pfizer inc intangible assets purchase price billion cash theoperating total assets acquired resultsof consumer healthcare business pfizer inc current liabilities bereported companys financial statements beginning noncurrent liabilities results subsequent acquisition date total liabilities assumed significant order obtain regulatory approval transaction net assets acquired company agreed divest certain overlapping businesses company completed divestiture zantacproduct theacquisition consumer healthcare business pfizer december divestitures kaopectate inc resulted billion goodwill allocated unisom cortizone balmexand actproducts consumer segment january thepreliminary purchase price allocation theidentifiable thefollowing table provides pro forma results operations intangible assets included current period balance sheet thefiscal year ended january fiscal year follows ended december consumer healthcare busi dollars millions ness pfizer inc acquired beginning intangible assets determinable lives period presentedthepro forma results include effect brands divestitures certain purchase accounting adjustments patents technology estimated changes depreciation andamortization expense acquired tangible intangible assets however customer relationships pro forma results include anticipated cost savings total amortizable intangibles effects planned integration consumer health brands indefinite lives care business pfizer inc accordingly amounts total intangible assets necessarily indicative results acquisition occurred dates indicated may occur future theweighted average life million total amortizable intangibles approximately years pro forma results majority intangible asset valuation relates year ended year ended december january brands assessment brands indefinite life dollars millions except per share data determinable life based number net sales factorsincluding competitive environment market share net earnings brand history product life cycles operating plan macro diluted net earnings per common share economic environment countries brands sold indefinitelife brands account thecompany process finalizing allocation thetotal value indefinitelife brands include listerine purchase price individual assets acquired liabilities nicorette neosporin sudafed benadryl visine assumed thepreliminaryallocation purchase price benylin determinablelife brands include purell included current period balance sheet based best actifed efferdentand regional country specific estimates management thecompletion purchase price brands determinablelife brands assetlives ranging allocation may result adjustments carryingvalue yearsthe patents technology intangibles consumer healthcare business pfizer incs recorded assets concentrated upper respiratory oral care medicated skin liabilities revisions useful lives intangible assets care tobacco dependence hair growth businesses determination residual amount allo assetlives ranging yearsthe estimated customer cated goodwill therelated depreciation andamortization relationship intangible assetuseful lives ranging acquired assets also subject revision based yearsreflect low historical projected customer attri final allocation tion rates among consumer healthcare business pfizer incs major retailer distributor customers theiprd charge related acquisition consumer healthcare business pfizer inc million pretax basis million aftertax basis primarily associated rights obtained pending switch zyrtecfrom us prescription counter status notes consolidated financial statements thevalue iprd calculated using cash flow projec probability ofsuccess factor ranging used tions discounted therisk inherentin projects aproba reflectinherent clinical regulatory risk discount rate bility success factor used reflectinherent applied regulatory risk discount rate applied theiprd charge related acquisition ensure company process completingthe analysis medical inc million associated femoral integration plans pursuant company incur costs artery closure device thevalue iprd calculated primarily related elimination certain duplicate selling using cash flow projections discounted therisk inherentin general administrative functions two companies projects aprobability success factor used areas global business services corporate staff reflectinherent clinical regulatory risk discount rate gotomarket support well excess manufacturing capacity applied addition acquisition consumer healthcare certain businesses acquired million cash business pfizer inc acquisitions included animas cor million liabilities assumed acqui poration leading maker insulin infusion pumps related sitions accounted purchase method accord products hand innovations llc privately held manufacturer ingly results operations included financial fracture fixation products theupper extremities future med statements respective dates acquisitions ical systems sa privately held company primarily devel theacquisitions included transform pharmaceuti ops manufactures markets arthroscopic fluidmanagement cals inc company specializing discovery superior systems vascular control systems inc privately held com mulations novel crystalline forms drugmolecules closure pany focused developing medical devices treat fibroids medical corporation company expertise intellectual control bleeding obstetric gynecologic applications property biosurgicals market peninsula pharmaceuticals groupe vendme sa privately held french marketer adult inc biopharmaceutical company focused developing baby skin care products colbar lifescience ltd privately commercializing antibiotics treat lifethreatening infections held company specializing reconstructive medicine tissue rights consumer andprofessionally dispensed rem engineering ensure medical inc privately held company brandtbrand oral care products whitening develops devices postcatheterization closure toothpastes strips systems mouth rinses femoral artery theexcess purchase price estimated fair value excluding acquisition consumer healthcare busi oftangible assets acquired amounted million ness pfizer inc excess purchase price esti assigned identifiable intangibleassets residual mated fair value tangible assets acquired amounted recorded goodwill approximately million million assigned identifiable intangibleassets identified value iprd primarily associated residual recorded goodwill approximately mil acquisitions transform pharmaceuticals inc closure medical lion identified value iprd primarily associ corporation peninsula pharmaceuticals inc ated acquisitions hand innovations llc future theiprd charge related acquisition transform medical systems sa vascular control systems inc colbar pharmaceuticals inc million associated lifescience ltd ensure medical inc research related discovery application superior theiprd charge related acquisition hand inno mulations thevalue iprd calculated using cash vations llc million associated fracture flow projections discounted therisk inherentin projects repair technologies thevalue iprd calculated using thediscount rate applied cash flow projections discounted therisk inherent theiprd charge related acquisition closure projects aprobability success factor ranging medical corporation million associated used reflectinherent clinical regulatory risk omnexsurgical sealant vascular indications outside discount rate applied europe potential indications worldwide thevalue theiprd charge related acquisition future med ofthe iprd calculated using cash flow projections dis ical systems sa million associated counted therisk inherentin projects aprobability nextra duo pump product technologies valueof success factor vascular indications iprd calculated using cash flow projections discounted indications used reflectinherent clinical regula therisk inherent projects probability success factor tory risk thediscount rate applied vascular technologies used reflect inherent clinical indications andregulatory risk discount rate applied theiprd charge related acquisition peninsula theiprd charge related acquisition vascular pharmaceuticals inc million associated control systems inc million associated development doripenem phase iii clinical flostat system technology thevalue iprd calcu trialsthevalue iprd calculated using cash flow lated using cash flow projections discounted therisk inherent projections discounted therisk inherentin projects projects aprobability success factor used aprobability success factor used reflect reflectinherent clinical regulatory risk discount inherent clinical regulatory risk discount rate rate applied appliedwas theiprd charge related acquisition colbar theremaining million iprd associated lifescience ltd million associated acquisition international commercial rightsto certain patents evolence family products biodegradable dermal knowhow field sedation analgesia scott fillers thevalue iprd calculated using cash flow lab inc thevalue iprd calculated using cash flow projections discounted therisk inherentin projects johnson johnson annual reportprojections discounted therisk inherentin projects warnings instructions usethat accompany prod thediscount rate ucts feasible predictthe ultimate outcomeof litiga certain businesses acquired million cash tion however company believes liability results million liabilities assumed acqui cases willbe substantially covered existing sitions accounted purchase method accord amounts accrued companys balance sheet ingly results operations included financial available thirdparty product liability insurance statements respective dates acquisition multiple products johnson johnson subsidiaries sub addition per terms acquisition agree ject numerous product liability claims lawsuits including ment link spine group inc million cash ortho evra risperdal duragesicand charit paid owners link spine group inc based artificial disc asofdecember approxi thedate us food drug administration fda mately claimants filed lawsuits made claims approved charitartificial disc thus total regarding injuries allegedly due ortho evra claimants cash expenditures related acquisitions million respect risperdal respect duragesic theacquisitions included mercks interest respect charit claimants seek sub johnson johnsonmerck consumer pharmaceuticals co stantial compensatory available punitive damages european nonprescription pharmaceutical joint venture includ numerous claims lawsuits united statesrelating ingall infrastructure brand assets managed drug propulsid withdrawn general sale com european joint venture egea biosciences inc exer panys janssen pharmaceutica inc subsidiary cise option acquire remaining outstanding stock resolved currentlyenrolled settlement programswith owned johnson johnson developed proprietary aggregate cap million paymentsby company technology platform called gene writer thatallows litigation concerning propulsidis pending canada rapid highly accurate synthesis dna sequences gene class action persons alleging adverse reactions drug assembly construction large synthetic gene libraries recently certifiedthe johnson johnson subsidiaries responsible artemis medical inc privately held company ultrasound marketing products vigorously defending xray visible biopsy site breast markers well hybrid claims except settlement deemed appropriate markers us commercial rightsto certain patents know field sedation analgesia scott lab inc affirmative stent patent litigation biapharm sas privately held french producer marketer patent infringement actions tried delaware federal district skin care products centered around leadingbrand biafine court late cordis corporation cordis subsidiary assets micomed privately owned manufacturer spinal johnson johnson obtained verdicts infringement patent implants primarily focused supplying german market validity damage awards boston scientific corpora acquisition ambiskin care brand women color tion boston scientific medtronic ave inc medtronic theexcess purchase price estimated fair value based number cordis vascular stent patents indecem tangible assets acquired amounted million ber jury damage action boston scientific assigned identifiable intangibleassets residual returned verdictof million thejury medtronic recorded goodwill million related us fda action returned verdictof million multiple posttrialpro approval charitartificial disc recorded addi ceedings appeals ensued respect verdicts tional goodwill associated link spine group inc ultimate outcomestill subject uncertainty acquisition thus total additions intangibles andgoodwill cordis also arbitration claim medtronic accus million approximately million ing medtronic infringement sale stent products introduced identified value iprd associated scott lab medtronic subsequent products subject earlier acquisition thevalue iprd calculated using cash action referenced subsequent products found flow projections discounted therisk inherentin projects licensed medtronic pursuant license thediscount rate arbitration panel march arbitration proceed supplemental pro forma information ings determine whether royalties owed products persfas business combinationsandsfas january cordis filed patent infringement action goodwill intangible assetsis provided boston scientific delaware federal district court impact aforementioned acquisitions mate accusing itsexpress taxusand libertestents infringing rialeffect companys results operations cash flows palmaz patentthatexpired november theliberte financial position stent also accused infringing cordis gray patent divestitures mate expires june jury found express rialeffect companys results operations cash flows taxusand libertestents infringed palmaz patent financial position libertestentalso infringed gray patent motions filed boston scientific seeking vacate verdictor obtain new trial denied june cordis expects boston scientific legal proceedings appeal us court appeals federal circuit product liability thecompany involved numerous product liability cases patent litigation various united states many concern adverse reactions johnson johnson subsidiaries drugs medical devices thedamages claimed substan theproducts various johnson johnson subsidiaries tial company confident adequacy thesubject various patent lawsuits outcomes notes consolidated financial statements couldpotentially adversely affect ability subsidiaries damages willfulness injunctive relief appeals sell thoseproducts require payment past damages decided future royalties respect matters trialof boston scientifics case asserting infringement johnson johnson subsidiary involved vigorously defending cypherstent boston scientifics grainger patent claims infringement disputing appro whichhadbeen scheduled march hasbeen adjourned priate validity enforceability patent claims pending decision cordis motion summary judgment asserted inthat case well boston scientific seeks injunction july jury federal district court delaware substantial damages found cordis cypherstent infringed boston scien boston scientific brought actions belgium andthe tifics ding patent cordis cypherand bx netherlands kastenhofer patent enjoin manufac velocitystents also infringed boston scientifics jang ture sale allegedly infringing catheters countries patent thejury also found patents valid boston recover damages thebelgian case pendingandno scientific seeks substantial damages injunction hearing date set decision lower court action june district court denied motions netherlands boston scientifics favor appeal cordis overturn jury verdicts grant new trial cordis germany boston scientific several actions based moved reconsideration decisions reconsider ding patents pending cordis cypherstent ation denied cordis appeal court appeals cordis successful actions trial level thefederal circuit thedistrict court indicated consider boston scientific appealed thefollowing chart summarizes various patent lawsuits concerning products johnson johnson subsidiariesthathave yet proceed trial jj plaintiff product company patents patent holder court trial date date filed catheters cordis fitzmaurice medtronic ave ed tex stent delivery systems drug eluting cordis grainger boston scientific del stents corp drug eluting cordis ding boston scientific germany stents corp twolayer cordis kasten boston scientific nd cal catheters hofer corp belgium forman stents cordis israel medinol multiple eu jurisdictions contact lenses vision nicolson ciba vision md fla care trial date established noninfringement invalidity unenforceability litigation filers ofabbreviated new drug patents event subsidiary company involved applications andas successful actions statutory month stay thefollowing chart indicates lawsuits pending generic expires ruling district court obtained firms filed abbreviated new drug applications seeking firms involved ability upon fda approval intro market generic forms products sold various subsidiaries duce generic versions product issue resulting company prior expiration applicable patents cover substantial market share revenue losses theproduct ing products theseandas typically include allegations companys subsidiary noted following chart month stays expired expire respect anda challenges regarding various products brand name patentnda generic trial date month product holder challenger court date filed stay expires aciphex eisai teva sd ny mg delay janssen dr reddys sd ny release tablet mylan sd ny axert almirall teva sd ny mg orthomcneil neurologics concerta mcneilppc andrx del none mg alza controlled release tablet johnson johnson annual reportbrand name patentnda generic trial date month product holder challenger court date filed stay expires ditropan xl orthomcneil mylan wv mg alza impax nd cal controlled release tablet ortho tri cyclenlo orthomcneil barr nj mg mg mg mg mg mg pepcidcomplete mcneilppc perrigo sd ny razadyne janssen teva del mylan del dr reddys del purepac del barr del par del alphapharm del razadyneer janssen barr nj risperdaltablets janssen mylan nj dr reddys nj mg tablets apotex nj risperdalmtab janssen dr reddys nj mg risperdaloral janssen apotex nj solution mgml topamax orthomcneil mylan nj mg tablet cobalt nj topamaxsprinkle orthomcneil cobalt nj mg capsule mylan nj trial date established action mylan dr reddys laboratories action mylan involving orthomcneils regarding risperdalrisperidone tablets mtabs product ditropan xloxybutynin chloride court district court new jersey ruled october thatthe september found ditropan xlpatentinvalid risperdalpatent valid enforceable infringed infringed mylans generic product thoserulings generic products issue entered injunction prohibiting affirmed court appeals federal circuit mylan dr reddys marketing generic risperidone september mylan impax received final fda products date earlier patent expiration decem approval launched products november ber mylan appealed ruling weeks following adverse ruling ditropan action mylan respect patent xlanda litigation mylan september johnson topamax district court new jersey october johnson andalza received seven antitrust class action grantedthe companys subsidiary orthomcneil pharma complaints filedby purchasers product allege ceutical incs orthomcneilmotion preliminary johnson johnson alza violated antitrust laws injunction barring launch mylan generic version various states knowingly pursuing baseless patent litigation oftopamax february district court granted thereby delaying entry market mylan impax orthomcneils motion summary judgment dismissing mylans claimthe patent obvious remaining issue case company expects judgment case shortly entered orthomcneil mylan appeal notes consolidated financial statements action impax involvingits anda referencing december orthomcneil received subpoena mcneilppcs product concerta mcneil alza corpo us attorneys office boston massachusetts seeking docu ration subsidiaries company dismissed preju ments relating marketing including alleged offlabel market dice claim infringement impax respect ing drugtopamaxtopiramate additional subpoena itsanda documents served june orthomcneil cooper respect matters johnson ating responding subpoenas october theus johnson subsidiary involved vigorously defending validity attorneys office boston asked attorneys orthomcneil enforceability asserting infringement cooperate facilitating subpoenaed testimony several itslicensors patents present former orthomcneil employees federal grand jury boston cooperation securing testimony average wholesale price awp litigation additional witnesses grand jury requested johnson johnson several pharmaceutical sub andis provided sidiaries along numerous pharmaceutical companies january janssen received subpoena defendants series lawsuits state federal courts office inspector general us office personnel involving allegations pricing marketing certain management seeking documents concerning sales market pharmaceutical products amounted fraudulent otherwise ingof payments physicians connection actionable conduct among things companies sales marketing clinical trials risperdal allegedly reported inflated average wholesale price awp risperidone documents subsequent thedrugs issue cases federal actions also requested additional subpoena seeking state actions removed federal court consoli information marketing adverse reactions dated pretrial purposes multidistrict litigation mdl risperdalwas received us attorneys office federal district court boston massachusetts theplaintiffs eastern district pennsylvania november janssen thesecases includeclasses private persons entities cooperating responding subpoenas paid portion purchase drugs issue based april several companys pharmaceutical awp state government entities thatmade medicaid pay companies requested submit information us ments thedrugs issue based awp mdl proceed senate finance committee use nominal pricing ing boston plaintiffs moved class certification exception calculating best price medicaid rebate portion claims august trial judge program request sent manufacturers top certified massachusettsonly classes private insurers provid twenty drugs reimbursed medicaid program ing medigap insurance coverage private payers physi companys pharmaceutical companies responded cianadministered drugs payments based awp request february request supplemental informa thejudge also allowed plaintiffs filea new complaint seeking tion received senate finance committee name proper parties represent national class individu responded companys pharmaceutical companies als made copayments physicianadministered drugs august johnson johnson health care systems covered medicare thecourt appeals declined allow inc hcs johnson johnson subsidiary received subpoena appeal issues january court certified dallas texas us attorneys office seeking documents national class noted trial two massachu relating relationships group purchasing settsonly class actions concludedbefore massachusetts organization novation hcs johnson johnson district court december decision expected subsidiaries thecompanys subsidiaries involved first quarter thetrial judge scheduled jurytrials responded subpoena begin april national class action behalf september ortho biotech inc ortho biotech individuals paid copayments medicare part b drugs received subpoena us office inspector generals trialin action broughtby attorney general state denver colorado field office seeking documents directed alabama making allegations related awp isset november sales marketing procritepoetin alfa additional awp cases broughtby various attorney gen present well dealings us oncology inc erals expected beset trial healthcare services network oncologists ortho biotech responded subpoena july centocor corporation received request thatit voluntarily provide documents information thecriminal division us attorneys office districtof new jersey connection investigation various centocor market ing practices subsequent requests documents received theus attorneys office thecompany centocor responded process responding requests documents information johnson johnson annual reportin march depuy orthopaedics inc depuy regarding sales marketing sideeffects risperdal johnson johnson subsidiary received subpoena well interactions state officials regarding states us attorneys office districtof new jersey seeking records formulary medicaidreimbursed drugs janssen concerning contractual relationships depuy process responding subpoena orthopaedics surgeons surgeonsintraining involved november centocor received subpoena hip knee replacement reconstructive surgery seeking documents connection investigation leading orthopaedic companies known received conducted office united states attorney similar subpoena depuy orthopaedics responding sub central district california regarding centocors average poena well followon subpoena documents number selling price asp calculations remicadeunder employees depuyhave subpoenaed testify companys contract purchase program centocor producing grand jury connection investigation material responsive subpoena andcooperating june us senate committee finance theinvestigation requested company produce information regarding use february johnson johnson voluntarily dis byseveral pharmaceutical subsidiaries educational closed us department justice doj us secu grants similar request sent major pharmaceutical rities exchange commission sec subsidiaries outside companies july committee specifically requested united states believed made improper payments information educational grants connection connection sale medical devices two small drug propulsid follow request received market countrieswhich payments may fall within jurisdiction committee additional information january foreign corrupt practices actthe company provide july scios inc scios johnson johnson sub additional information doj sec cooperate sidiary received subpoena us attorneys office agencies reviews matters district massachusetts seeking documents related september plaintiffs employment discrimina sales marketing natrecor scios responding tion litigation initiated company federal subpoena early august scios advised district court new jersey moved certify class investigation wouldbe handled us attorneys office african american hispanic salaried employees com northern district california san francisco pany affiliates us employed time september johnson johnson received sub november present plaintiffs seek monetary poena us attorneys office districtof massachusetts damages theperiod present including seeking documents related sales marketing eight drugs punitive damages equitable relief thecourt denied plain omnicare inc amanager pharmaceutical benefits tiffs class certification motion december theplaintiffs longterm care facilities thejohnson johnson subsidiaries sought reconsideration decision thecompany dis involved responding subpoena several employees putes allegations lawsuit vigorously defending ofthe companys pharmaceutical subsidiaries subpoenaed testify grand jury connection thecompany along whollyowned subsidiaries thisinvestigation ethicon inc ethicon endosurgery inc hcs defendants january janssen received civil investigative federal antitrustaction challenging suture endo demand texas attorney general seeking broad cate mechanical contracts group purchasing organizations gories documents related sales andmarketing hospitals discounts predicated hospital achiev risperdal janssen responding request october ing specified market share targets categories prod texas attorney general joined qui tam action filed ucts trialin action conmed v johnson johnson et al janssen texas state court alleging label marketing sdny filed november currently scheduled risperdaland seeking compensation alleged adverse april conmed alleges damages billion reactions due risperdal damages wouldbe trebled antitrust laws dam february johnson johnson received subpoena ages liability successfully established trial late us securities exchange commission sec request december early three purported class actions ing documents relating participation several johnson filed behalf purchasers endomechanical instru johnson subsidiaries united nations iraq oil food ments actions filed federal district court program thesubsidiaries cooperating sec pro thecentral district california ducing responsive documents november amgen filed suit hoffmann june depuy received subpoena us laroche inc us district court thedistrict massa department justice antitrust division requesting documents chusetts seeking declaration rocheproduct cera related manufacture marketing sale orthopaedic roche indicated seek introduce devices search warrants executed connection united states infringes number amgen patents concerning investigation depuy responding request docu epo amgen licenses manufactures epo salein ments wake publicity subpoenadepuy served five civil antitrustclass actions september janssen received subpoena attorney general state california seekingdocuments notes consolidated financial statements united states companys ortho biotech inc subsidiary thediluted net earnings per share calculation includes dilu nondialysis indications thesuit preliminarystages tive effect convertible debt decrease interest expense october wyeth inc initiated litigation delaware million million million tax years cordis corporation alleging cordis breached respectively license supply agreement pursuant wyeth supplies diluted net earnings per share excludes millionmillion cordis drug rapamycin used connection million shares underlying stock options cordis cyphersirolimuselutingstent cordis com respectively exercise price options wasgreater menced action delaware seeking declaration average market value wouldresult anti breach occurred dilutive effect diluted earnings per share thecompany also involved number patent trademark lawsuits incidental business theulti capital treasury stock mate legal financial liability company respect claims lawsuits proceedings referred changes treasury stock estimated certainty however companys opin amounts millionsexcept treasury stock treasury stock ion based examination matters experience number shares thousands shares amount date discussions counsel theultimate outcomeof legal balance december proceedings net liabilities accrued companys balance employee compensation stock option plans sheet expected material adverse effect conversion subordinated debentures companys financial position although resolution repurchase common stock reporting period one matters couldhave significant impact companys results operations balance january cash flows period employee compensation stock option plans conversion subordinated debentures repurchase common stock earnings per share balance january thefollowing reconciliation basic net earnings per share employee compensation stock option plans diluted net earnings per share theyears ended december conversion subordinated debentures january january repurchase common stock shares millions except per share data balance december basic net earnings per share average shares shares common stock issued shares outstandingbasic end potential shares exercisable cash dividends paid per share com stock option plans pared dividends per share per less shares repurchased share treasury stock method convertible debt shares adjusted average shares outstandingdiluted diluted net earnings per share johnson johnson annual report selected quarterly financial data unaudited selected unaudited quarterly financial data theyears summarized first second third fourth first second third fourth dollars millions except per share data quarter quarter quarter quarter quarter quarter quarter quarter segmentsales customers consumer pharmaceutical med devices diagnostics total sales gross profit earnings provision taxes income net earnings basic net earnings per share diluted net earnings per share first quarter includes aftertax gain million guidant acquisition termination fee aftertax charge million inprocess research development iprd second quarter includes aftertax charge million iprd third quarter includes aftertax charge million iprd fourth quarter includes aftertax charge million iprd second quarter includes aftertax charge millionfor iprd million tax benefit dueto reversal tax liability related technical correction associated american jobs creation act fourth quarter includes aftertax charge million iprd shifts sales lower tax jurisdictions expenditures higher tax jurisdictions significant impact fiscal fourth quarters tax rate subsequent events fiscal first quarter company completed acquisition conor medsystems inc acardiovascular device company billion cash fiscal first quarter accordance regulatory approval acquisition consumer healthcare business pfizer inc company announced closing divestiture kaopectate unisom cortizone balmexand actproducts chattem inc million cash notes consolidated financial statements managements report internal control financial reporting section sarbanesoxley act information communication andmonitoringthecom management required assess effectiveness panys assessment included extensive documenting evaluating companys internal control financial reportingas theendof testing design operating effectiveness internal fiscal year report based onthat assessment whether controls financial reporting thecompanys internal control financial reportingis effective december company completed theacqui management company responsible establish sition consumerhealthcare business pfizer inc due ingand maintaining adequate internal control financial close proximity completiondate ofthe acquisition reporting thecompanys internal control financial report date ofmanagements assessment effectiveness ingisdesigned provide reasonable assurance reliabil companys internal controlover financialreporting management ity companys financial reporting preparation excluded consumerhealthcare business pfizer inc financial statements accordance generally accepted assessment internal controlover financialreporting accountingprinciples thetotal assets consumer healthcare business internal controls financial reporting matter well pfizer inc primarily intangible assets goodwill designed inherent limitations therefore internal control represented companys total assets fiscal financial reporting determined effective provide year ended december reasonable assurance respect financial statement theoperating results consumer healthcare business preparation may prevent detect misstatements pfizer inc acquired december reported moreover projections evaluation effectiveness future companys financial statements beginning periods subject risk controls may become inade results subsequent acquisition date significant quate changes conditions degree based companys processes assessment compliance policies procedures may deteriorate described abovemanagement concluded thecompanys management assessed effective december companys internal control finan ness companys internal control financial reporting cial reporting effective ofdecember making assessment company managements assessment effectiveness used criteria establishedby committee sponsoring companys internal control financial reporting decem organizations treadway commission coso internal ber audited pricewaterhousecoopers llp controlintegrated frameworkthesecriteria areas independent registered public accounting firm stated ofcontrol environment risk assessment control activities report appears herein johnson johnson annual reportreport independent registered public accounting firm shareholders board directors audit conducted audit internal control financial johnson johnson reporting accordance standards public company accounting oversight board united states completed integrated audits johnson johnsons standards require plan perform audit obtain consolidated financial statements internal control reasonable assurance whether effective internal control financial reporting december accordance financial reporting maintained material respects standards public company accounting oversight audit internal control financial reporting includes board united states opinions based audits obtaining understanding internal control financial presented reporting evaluating managements assessment testing evaluating design operating effectiveness internal consolidated financial statements control andperformingsuch procedures consider opinion accompanying consolidated balance sheets necessary circumstances believe audit related consolidatedstatements earnings statements provides reasonable basis opinions equity statements cash flows present fairly mate companys internal control financial reporting rialrespects financial position johnson johnson process designed provide reasonable assurance regarding subsidiaries companyat december janu reliability financial reporting preparation financial ary results operations cash statements external purposes accordance generally flows three years period ended december accepted accountingprinciplesa companys internal control conformity accountingprinciples generally financial reporting includes policies procedures accepted united states america financial state pertain maintenance records reasonable ments responsibility companys management detail accurately fairly reflect transactions disposi responsibility express opinion financial state tions assets company ii provide reasonable ments based audits conducted audits assurance transactions recorded necessary permit statements accordance standards public com preparation financial statements accordance generally pany accounting oversight board united states stan accepted accountingprinciples receipts expendi dards require plan perform audit obtain tures company made accordance reasonable assurance whether financial statements authorizations management directors company free material misstatement audit financial state iii provide reasonable assurance regarding prevention ments includes examining test basis evidence supporting timely detection unauthorized acquisition use disposition amounts disclosures financial statements assess companys assets couldhave material effect ing accounting principles used significantestimates financial statements made management evaluating overall financial state ofits inherent limitations internal control ment presentation believe audits provide reason financial reporting may prevent detect misstatements able basis opinion also projections evaluation effectiveness future peri discussed note due theimplementation sfas ods subject risk controls may becomeinadequate company changed manner itaccounts changes conditions degree compli pensions benefits december ance policies procedures may deteriorate described managements report internal control internal control financialreporting financial reporting management excluded con also opinion managements assessment included sumer healthcare business pfizerinc assessment accompanying managements report internal control internal control overfinancial reporting december financial reporting company maintained effective acquired company december internal control financial reporting december alsoexcluded consumerhealthcare business based oninternal control integrated frameworkissued pfizerinc audit internal control overfinancial report committee sponsoring organizations treadway com ing total assets consumerhealthcare business pfizer mission coso fairly statedin material respects based inc represent related consolidated financial statement criteria furthermore opinion company amounts ofdecember maintained material respects effective internal control financial reporting december based crite ria established ininternal control integrated frameworkissued coso thecompanys management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting responsibility express opinions new york new york managements assessment effectiveness com february panys internal control financial reporting based report independent registered public accounting firm summary operations statistical data dollars millions except per share figures sales customersus sales customersinternational total sales cost products sold selling marketing administrative expenses researchexpense purchased inprocess research development interest income interest expense net portion capitalized income expense net earnings provisionfor taxes income provisionfor taxes income net earnings percent sales customers diluted net earnings per share common stock percent return average shareholdersequity percent increaseoverpreviousyear sales customers diluted net earnings per share supplementary expense data cost materials services total employment costs depreciation amortization maintenance repairs total tax expense supplementary balance sheet data property plant equipment net additions property plant equipment total assets longterm debt operating cash flow common stock information dividends paid per share shareholdersequity per share market price per share yearend close average shares outstanding millionsbasic diluted employees thousands netof interest income also included cost materials services category includes taxes income payroll property otherbusiness taxes summary operations statistical datashareholder return performance graphs ear umulat e otal shareholderreturn johnson johnson n h n h n n ear gr jj h year ear umulat e otal shareholderreturn johnson johnson n h n h n n ear gr jj h shareholder return performance graphs ra year ra shareholder return performance graphs johnson johnson n h n h n n johnson johnson n h n h n n rreconciliation nongaap financial measures tableis provided reconcilecertain financial disclosures letter shareholders vs vs dollars millions except per share data change change net earningsas reported inprocess research development iprd charges guidant acquisition agreement termination fee american jobs creation act ajca tax cost associated repatriation undistributed international earnings tax gain associated technical correction net earningsas adjusted diluted net earnings per shareas reported inprocess research development charges guidant acquisition agreement termination fee american jobs creation act tax cost associated repatriation undistributed international earnings tax gain associated technical correction diluted net earnings per shareas adjusted thecompany believes investors gain additional perspective underlying business trends results providing measure net earnings diluted net earnings per share excludes iprd charges guidant acquisition agreement termination fee tax cost associated funds repatriated tax gain associated technical correction made ajca order evaluate ongoing business operations thesenongaap financial measures considered replacements read together mostcomparable gaap financial measures reconciliation nongaap financial measuresprincipal office company required file dividend reinvestment plan one johnson johnson plaza exhibit fiscal year plan allows full partial new brunswick new jersey certifications section dividend reinvestment additional sarbanesoxley act signed chief monthly cash investments per executive officer chief financial year johnson johnson common stock annual meeting officer addition company required without brokerage commissions service annual meeting shareholders take submit certification signed chief charges stock purchases place april hyatt regency executive officer new york stock interested participating plan new brunswick albany street new exchange within days following need authorization form andor brunswick new jersey meeting annual meeting shareholders copies information please call computershare convene shareholders certifications filed previous years trust company na cordially invited attend formal notice posted companys corporate outside us meeting proxy statement proxy governance web site future certifica sent shareholders hearing impaired tions posted promptly upon filing shareholders inquiries corporate governance common stock regarding stockrelated matters copies companys annual report listed new york stock exchange communicate directly computershare quarterly reports form stock symbol jnj trust company na via telecommunica q current reports form k tions device tdd telephone number securities exchange commission shareholder relations contact service proxy statement annual report steven rosenberg outside us available online wwwjnjcom share corporate secretary holders without charge upon written request registered shareholders wish receive secretary companys principal investor relations contact electronic notice online access future address calling louise mehrotra annual reports proxy materials instead outside us vice president investor relations paper copies may register online addition companys wwweconsentcomjnj corporate governance web site web site wwwinvestorjnjcomgovernance transfer agent registrar wwwjnjcom shareholders see companys questions regarding stock holdings principles corporate governance information certificate replacementtransfer dividends charters audit committee johnson johnson history address changes directed compensation benefits committee wwwkilmerhousecom computershare trust company na nominating corporate governance royall st entire contents committee policy business conduct canton johnson johnson employees code business conduct ethics members outside us board directors executive officers internet wwwcomputersharecomjnj copies documents available shareholders without charge upon written request secretary companys paper used publication made postcon principal address sumer recycled fiber forest stewardship council certified chain custody manufactured green energy credits purchase electricity generated renewable energy sources wind lowimpact hydro resources checkmarkandtree logo forest stewardship council following trademarks trade names johnson johnson affiliated companies appear report day acuvue day acuvue define day acuvue moist warming active naturals active photobarrier complex acuvue acuvue advance acuvue oasys advantage alza ambi ambi even clear angioguard animas aveeno aveeno ultra calming babycenter bandaid benadryl biosense webster carefree carto cellsearch centocor charite cilag gmbh international clean clear compeed consta contour transtar cordis cortaid cypher select dacogen depuy depuy asr depuy microhip depuy mitek depuy orthopaedics depuy proxima discover doxil duragesic etrans echelon endopath endopath ets endopath xcel eprexerypo ethicon ethicon endosurgery ethicon omnex evotech floxin genesearch gotabs groupe vendome gynecare morcellex gynecare tvt secur harmonic ace harmonic wave helioplex invega ionsys janssencilag janssen pharmaceutical kk johnson johnson johnson johnson pediatric institute johnsons jurnista ky laboratories vendome lacreon le petit marseillais lifescan ligamax listerine lubriderm mammotone mcneil microtip milagro natrecor neosporin neutrogena neutrogena mineral sheers nicorette onetouch onetouch horizon onetouch ultra onetouch ultraeasy onetouch ultramini oros ortho ortho biotech orthoclinical diagnostics porocoat precise prezista primage procriteprex quick pack reach reach cleanpaste reach inbetween rembrandt remicade risperdal risperdal consta risperdal mtab sensual mist softlotion softwash soothing naturals splenda stayfree sudafed surgiflo tibotec topamax touch massage tylenol ultram ultrapro velcade veridex viactiv virco visine vistakon vitros xianjanssen pharmaceutical yondelis zarnestra following trademarks companies also appear report aciphexpariet eisai co ltd acuson acunav siemens medical solutions associado saude de familia china hospital management association chinese ministry health division child health conservation fund crescendo clearstream techonologies group plc dacogen mgi pharma elizabeth glaser pediatric aids foundation forest stewardship council glen c olsen hospital project mercy green power partnership healthy communities healthy ecosystems world wildlife fund insead kentucky department public health levaquin daichi pharmaceutical co march dimes prematurity prevention medhanealem school project mercy nature conservancy neonatal resuscitation program regatta brivant ltd safe kids worldwide trust public land ucla management development institute ultram er biovail corporation us environmental protection agency velcade millennium pharmaceuticals inc wilderness society world wildlife fund yondelis pharmamar corporate shareholder informationour credo believe first responsibility doctors nurses patients mothers fathers others use products services meeting needs everything must high quality must constantly strive reduce costs order maintain reasonable prices customers orders must serviced promptly accurately suppliers distributors must opportunity make fair profit responsible employees men women work us throughout world everyone must considered individual must respect dignity recognize merit must sense security jobs compensation must fair adequate working conditions clean orderly safe must mindful ways help employees fulfill family responsibilities employees must feel free make suggestions complaints must equal opportunity employment development advancement qualified must provide competent management actions must ethical responsible communities live work world community well must good citizenssupport good works charities bear fair share taxes must encourage civic improvements better health education must maintain good order property privileged use protecting environment natural resources final responsibility stockholders business must make sound profit must experiment new ideas research must carried innovative programs developed mistakes paid new equipment must purchased new facilities provided new products launched reserves must created provide adverse times operate according principles stockholders realize fair return one johnson johnson plaza new brunswick new jersey